Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2026 Jul 10;22(7):e1012151. doi: 10.1371/journal.pgen.1012151

Sex differences in the regulation and function of cellular immunity in Drosophila

Alexandra Dvoskin 1, Kevin Y L Ho 1,2, Michael Allara 3, Nicola Janz 1, Elizabeth Rideout 1, Juliet R Girard 3, Guy Tanentzapf 1,*
Editor: Pablo Wappner4
PMCID: PMC13399539  PMID: 42430458

Abstract

Sex differences in development and physiology are prevalent in animals. One physiological system with pronounced differences between the sexes is the immune system: the immune response in humans differs between sexes and results in differential susceptibility of males and females to autoimmune diseases, malignancies, and infectious diseases. However, much remains to be discovered about the mechanisms underlying these sex-based differences in immunity. Here, we use the Drosophila hematopoietic organ, the lymph gland, as a model to investigate sex differences in cellular immunity and determine the underlying mechanisms. We find that, in line with their smaller body size, males have smaller lymph glands than females that contain fewer blood progenitors and produce less immune cells. Single cell RNA-seq analysis of the lymph gland showed that they expressed sex determination genes and identified substantial sex-specific differences in gene expression. By manipulating the sexual identity of different cell types in the lymph gland we show that a subset of these sex differences are controlled by organ-intrinsic mechanisms involving the hematopoietic niche. Importantly, we find a differential response between males and females to changes in insulin signaling, an important regulator of the immune response in the niche. Finally, we provide evidence for differences in the cellular immune response following infection between males and females. Overall, our results provide mechanistic insight into how sex differences in immunity are established.

Author summary

Our paper deals with a fundamental question in biology, how does the sex of an organism influence its anatomy and physiology. In particular, we focus on sex-differences in immunity and stem cell function. We establish the Drosophila larva as a model for analysing sex-based differences in cellular immunity. Cellular immunity in Drosophila is based on the production of multiple types of mature immune cells from blood progenitors and takes place in the fly hematopoietic organ, the larval lymph gland. We find that sex controls the number of various cell types in the lymph gland (progenitors, and specific varieties of mature blood cells). These sex-differences vary by cell type and change depending on whether flies are raised under homeostatic or infection conditions. We provide insight into the mechanisms that mediate these sex differences, identifying a possible role for the hematopoietic niche and insulin signaling. Taken together our work not only serves as an initial characterization of baseline sex-differences in fly hematopoiesis and cellular immunity but also identifies important areas for future exploration.

Introduction

Sex differences exist across many species, where such differences reflect variations in reproductive strategies, ecological roles, and physiological demands [1,2]. In many animals, males and females differ in terms of overall body size, muscle mass, fat storage, and reproductive tissue development [313]. These differences often arise early in development, persist throughout life, and manifest at multiple levels, from the individual cell, to tissues, organs, and entire organisms. Sex differences are genetically encoded and typically involve hormonal signals that control animal development and homeostasis [14]. Drosophila has proven to be a powerful model for exploring the genetic underpinning and signaling mechanisms that underlie sex differences [1518]. In Drosophila, sex differences arise early, appearing during embryogenesis, and are pronounced in the adults. Drosophila males are typically smaller than females, and exhibit marked differences from females in appearance, behavior, and physiology.

It is well established, both in epidemiological and experimental studies, that there are extensive sex differences in immunity in humans [19,20]. This has important implications in health and disease, as evidenced, for example, by sex differences in the ability to fight certain infections, respond to vaccines, or by the higher prevalence of multiple autoimmune conditions in females. It is speculated that sex differences in immunity are attributed to either genetic or hormonal factors and several mechanistic differences in immunity have been uncovered. On a cellular level, innate detection of pathogens is known to differ between males and females, as sex differences have been found in the induction of toll-like receptors (TLR) and the antiviral type I interferon (IFN) response [21,22]. Moreover, in both humans and rats, females show a higher activity of monocytes, macrophages and dendritic cells [23,24]. Females also tend to mount a more robust adaptive immune response than males by having a higher proportion of active T cells during certain viral infections [25], as well as increased expression, associated with estrogen response elements in their promoter regions, of antiviral and inflammatory genes [26].

Although immunology studies in humans have increasingly included sex as a variable, this has not been the case in Drosophila, an important genetic model system for immunity. A recent literature survey found that out of over 1000 papers about the adult immune system in Drosophila, almost half did not report sex and only 13% reported results for both males and females separately [27]. In the small number of published immunology studies in Drosophila that took sex into account, it has been found that there were differences in immune response and survival following infection, with outcomes being pathogen specific. Specifically, viral infections have been found to result in a higher rate of mortality in males than females, with surviving females exhibiting increased infertility [28]. Bacterial infection studies have shown a complex picture, with sex differences in survival rates following infection in certain strains of bacteria, regardless of whether the bacterial strain in question was gram negative or gram positive [2933]. For example, females were shown to be more susceptible to infection with Enterococcus faecalis but less susceptible to S. aureus or to Lactococcus lactis infection, all of which are gram positive bacteria [27,31,32]. Some of this variation is accounted for by sex-specific differences in the regulation of both IMD and Toll immune pathways between males and females following infection [30,31]. There is also some indirect evidence of sex differences in the cellular immune response, specifically, hemocytes functioning downstream of the Jun N-terminal kinase (JNK) pathway in repairing tissue damage induced by UV irradiation were only seen in males [34,35].

Work in Drosophila on hematopoiesis and immunity has focused extensively on the lymph gland, an organ that is responsible for the cellular immune response during larval stages [36]. The primary lobe of the lymph gland is the main site of hematopoiesis in Drosophila larval stages and is typically described as being made up of 3 distinct zones: the Posterior Signaling Center (PSC), a group of a few dozen cells that are thought to have a stem cell niche-like function, the medullary zone (MZ), which houses blood progenitors, and the cortical zone (CZ) which holds differentiated blood cells [37]. Multiple signaling pathways act in the lymph gland to regulate hematopoiesis including the Wingless, Hedgehog, JAK/STAT, BMP and Notch pathways [3742]. Mutations that perturb these signaling pathways result in a variety of defects in lymph gland homeostasis, ranging from depletion of the progenitor population, overproduction of various mature blood cell lineages, and expansion of the PSC [3841,43]. Another major signaling pathway known to act in the lymph gland is the insulin/insulin-like growth factor signaling pathway (IIS) [4446]. In the lymph gland, the IIS pathway has been shown to regulate both the maintenance and differentiation of blood progenitors as well as maintenance of the PSC [47,48]. Moreover, at least two Drosophila insulin-like peptides (ILPs), secreted by insulin-producing cells in the brain (Ilp2) and the fat body (Ilp6), are known to act in the lymph gland to control hematopoiesis [4952].

Here we analyzed sex differences in the Drosophila lymph gland under homeostatic conditions as well as following bacterial infection. We identified sex differences in the overall cell number and within specific cell types of the lymph gland. Analysis of single-cell RNA-Seq data from the lymph gland uncovered extensive sex-differences in gene expression in all cell types of the gland. Further investigation into the mechanisms that mediate sex-differences identified a source of some of the relevant regulatory signals, revealing a role for insulin signaling in this process. Finally, we explored whether and how sex differences extend to the cellular immune response following infection.

Results

Lymph glands exhibit sex differences

To investigate whether there were sex differences between lymph glands in male and female larvae, we measured organ size in late 3rd instar larva using automated cell counts with custom image analysis software (see Methods). We found that lymph glands from male larvae contained an average of 1587 ± 404 cells (n = 59), while lymph glands from females contained on average 2183 ± 501 (n = 63), a difference of ~37% in cell number (Fig 1G). Next, we determined the number of cells in the Posterior Signaling Centre (PSC), the stem cell niche of the lymph gland by staining with an antibody that labels the transcription factor Antennapedia (Antp) and performing cell counts (see methods). These counts showed that lymph glands from male larvae contained an average of 68 ± 22 PSC cells (n = 59), while lymph glands from female larvae contained on average 91 ± 24 PSC cells (n = 63), a difference of ~33% (Fig 1H). We noted that these numbers of PSC cells we recorded were higher than the numbers we and other groups previously reported (for example we reported ~45 PSC cells in Ho et al, 2021). This could partly be explained due to differences in methodology, as we used an antibody staining against Antp to do our PSC counts (S1 Fig), while others used different methods. However, methodology alone did not account of for all of these differences and may represent genotype specific variation. Next, we labelled progenitors in the lymph gland in two ways, using either Tep4gal4; UAS-GFP to mark core progenitors or domeMESO GFP to mark the total population of progenitors [51]. Cell counts of either the total or core progenitor populations showed that lymph glands from male larvae contained an average of 636 ± 190 core progenitors (n = 59) and 909 ± 297 (n = 26) total progenitors, while lymph glands from female larvae contained on average 830 ± 282 core progenitors (n = 63) 1205 ± 421 (n = 24) total progenitors, a difference of ~33% in both populations (Fig 1I and 1L).

Fig 1. Characterizing sex differences in the lymph gland.

Fig 1

(A-E) Representative images of the female w1118 x tep4 gal4GFP lymph gland stained with ToPro, as well as Antp (B) to mark for PSC cells, endogenously expressed GFP in tep4 + cells (C) to mark progenitors, Hnt (D) to mark for crystal cells, and P1 (E) to mark for plasmatocytes. (F) Representative image of the female w1118 x domeMESO GFP lymph gland stained with ToPro. (A’-E’) Representative images of the male w1118 x tep4 gal4GFP lymph gland stained with ToPro, as well as Antp (B’) to mark for PSC cells, endogenously expressed GFP in tep4 + cells (C’) to mark progenitors, Hnt (D’) to mark for crystal cells, and P1 (E’) to mark for plasmatocytes. (F’) Representative image of the male w1118 x domeMESO GFP lymph gland stained with ToPro. (G-L) Raw cell counts plotted for both males and females. (G) Raw number of nuclei, used to measure organ size, plotted for males and females (female n = 64, male n = 59, p < 0.0001). (H) Raw number of PSC cells (Antp+), plotted for males and females (female n = 64, male n = 59, p < 0.0001). (I) Raw number of core progenitors (tep4+), plotted for males and females (female n = 64, male n = 59, p < 0.0001). (J) Raw number of crystal cells (Hnt+), plotted for males and females (female n = 25, male n = 19, p < 0.0001). (K) Raw number of plasmatocytes (P1+), plotted for males and females (female n = 30, male n = 22, p = 0.1661). (L) Raw number of total progenitors (domeMESO+), plotted for males and females (female n = 24, male n = 26, p = 0.0058). (G’-K’) Corrected by dividing each female data point by average phenotype weight (w1118 x tep4 gal4GFP=2.24mg, w1118 x domeMESO GFP = 2.19mg)and dividing each male data point by average phenotype weight (w1118 x tep4 gal4GFP=1.72mg, w1118 x domeMESO GFP = 1.65mg). (G’) Corrected nuclei count, used to measure organ size (female n = 64, male n = 59, p = 0.2107). (H’) Corrected number of PSC cells (Antp+) (female n = 64, male n = 59, p = 0.7819). (I’) Corrected number of core progenitors (tep4+) (female n = 64, male n = 59, p = 0.9705). (J’) Corrected number of crystal cells (Hnt+) (female n = 25, male n = 19, p = 0.0056). (K’) Corrected number of plasmatocytes (P1+) (female n = 30, male n = 22, p = 0.4531). (L’) Corrected number total progenitors (domeMESO+) (female = 24, male = 26, p = 0.6048). **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars are 95% CI.

A key required control for interpreting these data is that the drivers themselves are expressed at similar levels between males and females. To study this question, we analysed the efficiency of two lymph gland drivers, Tep4gal4 and collier-gal4, in males and females. Both drivers were used to express GFP and, using imageJ, we measured intensity across a variety of images with the same imaging settings (laser power, gain and offset). We did this by going through slices of images, finding full cells that were not overlapped with other cells, and measuring expression intensity (see materials and methods). Our results (S2 Fig) show no significant difference between male and female mean intensity for collier-gal4 (p = 0.0740), or for Tep4gal4 (p = 0.5192).

To determine the number of mature differentiated plasmatocytes and crystal cells we stained the lymph gland with antibodies against the markers P1 and Hindsight (Hnt), respectively, followed by whole lymph gland cell counts (see methods). These cell counts showed that in lymph glands from male larvae there were on average 22 ± 17 crystal cells (n = 20) and 335 ± 134 plasmatocytes (n = 22), respectively. In comparison, in lymph glands from female larvae there were on average of 46 ± 18 crystal cells (n = 28) and 409 ± 172 plasmatocytes (n = 29), a difference of ~210% in crystal cell numbers and ~22% in plasmatocyte numbers between the sexes (Fig 1J-1K).

Because Drosophila male larvae are smaller in size than females, we asked if the sex differences we observed between lymph glands from male and female larvae were consistent with the overall size differences between males and females. To account for known sex differences in body size we normalized lymph gland cell counts to body size (see methods, Fig 1G’-1L’). This analysis showed that sex differences in most parameters were eliminated when normalized for body size. Furthermore, normalizing the number of PSC cells, core and total progenitors or plasmatocytes to lymph gland size, measured as the total number of nuclei, which is common practice done in the field, also eliminated sex-based differences (S3 Fig). Importantly, the female bias in crystal cell number was maintained after normalizing for body size. Crystal cell numbers are known to be affected by the lymph gland size, and for this reason, it is common to report the overall percentage crystal cell in the lymph gland rather than raw counts. We therefore asked if normalizing for the total number of cells within the lymph gland differed from normalizing to body size. Our data, shown in S4 Fig, showed that similar conclusions could be drawn by normalizing crystal cell numbers to either body size or the total numbers of cells in the lymph gland. Taken together, our data shows striking sex differences in both overall organ size as well as the size of specific cell populations in the larval lymph gland. While these differences generally align with expected organ size based on body size, crystal cells show a uniquely large population size increase in females, that exceeds what would be expected based on overall trends in body size.

RNA sequencing shows differential gene expression between sexes in the lymph gland

In our previous single cell RNA sequencing analysis of lymph glands, we excluded several sex-specific genes prior to graph-based clustering or visualization. Reanalysis of this data including sex-specific genes shows that sex has a significant effect on the UMAP visualization of lymph gland cells. Specifically, we see two distinct hemispheres in the UMAP, one of which is distinguished by high expression of the male-specific long non-coding RNAs (lncRNAs) lncRNA:roX1 and lncRNA:roX2 (S1 Movie). Since we added the same number of male and female larvae to each sample, and roughly half of the cells express roX1 and roX2, this suggests that sex is what distinguishes the two hemispheres of the UMAP. Some of the graph-based cell clusters are physically split across the distinct hemispheres in the three-dimensional UMAP (S1 Movie). The affected clusters correspond to lymph gland progenitors (MZ), intermediate cells (IZ and proPL), and plasmatocytes (PL; S1 Movie).

We used the expression levels of both roX1 and roX2 to disaggregated cells by sex. Cells with high roX1 and roX2 expression (8865 in total, ~ 42% of cells) were categorized as male, while cells with low roX1 and roX2 expression (10242 in total, ~ 48% of cells) were categorized as female. Cells which showed high expression of one roX RNA but not both (2050 in total, ~ 10% of cells) were excluded from further analysis as their sex was ambiguous. When we compared gene expression across the sexes, we observed differential expression of several genes involved in sex determination. For example, we saw that msl-2 was enriched in male cells, but Sxl and tra were enriched in female cells (Fig 2A and S1 Table). These data suggest that the sex determination genes are expressed in lymph gland cells.

Fig 2. Single-cell RNA sequencing of lymph gland cells.

Fig 2

(A-B) Bubble plots showing the mean expression (Mean) of each gene (color intensity) and percentage (Pct) of those cells which express that gene (size). (A) Expression of known sex-specific genes in the scRNA-data that have been disaggregated by sex. lncRNA:roX1, lncRNA:roX2, and msl-2 are enriched in male cells while Sxl and tra are enriched in female cells. (B) Selected genes that were found to be enriched in male or female cells in specific lymph gland zones. PSC, posterior signaling center; MZ, medullary zone; IZ, intermediate zone; proPL, proplasmatocyte; PL, plasmatocyte; X, mitotic cluster; CC, crystal cell.

We identified differentially expressed genes (DEGs) which were significantly enriched in either males or females using ANOVA analysis (genes that were greater than or equal to the fold change threshold of 1.5 and less than or equal to the false discovery rate threshold of 0.0001 were defined as significantly enriched; S1 File). We then compared gene expression of male and female cells in each graph-based cluster including the PSC, MZ, IZ, proPL, X, PL, and CC. This allowed us to determine sex-specific differences within each cell type. While some sex-specific DEGs are differentially expressed across all populations of male or female lymph gland cells, many are only differentially expressed in male or female cells in one or more specific zones (S1 File). For example, female PSC cells are uniquely enriched in TkR99D, which encodes a receptor for tachykinin-like neuropeptides, while male PSC cells are specifically enriched for rdgA, a gene encoding a diacylglycerol kinase involved in phospholipase C signaling (Fig 2B). To identify potential pathways or processes involved in each cluster by sex, we performed gene set enrichment analysis on the sex-specific DEGs we identified in each cluster (S1 File). For example, we found that female MZ, IZ, proPL, and PL cells were enriched in genes involved in the humoral immune response downstream of the Toll and Imd signaling pathways (CecB; Fig 2B and S1 File). Overall, many of the sex-specific DEGs we identified have human orthologs and some have been previously implicated in blood development, disease, or immune function (S1 File). These sex-specific genes are of interest for future study and may provide insight into the mechanisms that underlie sex differences in hematopoiesis or immunity.

We find no evidence that Sex differences in the lymph gland are mediated by the CNS

Sex differences between tissues can arise due to cell-autonomous or non-cell-autonomous mechanisms. For example, it has been shown that systemic signals from tissues such as the fat body, the muscles, or the central nervous system (CNS) can influence cell and body growth in the fly [4951]. To test whether sex differences in the lymph gland were due to a systemic signal originating from the CNS or fat body, we employed a strategy where we feminized these tissues in an otherwise genetically male fly and asked how this impacted overall organ size as well the size of individual cell populations in the lymph gland. To change the sexual identity of different tissues we expressed sex determination gene transformer (tra) in males [15,16,5360]. Normally, a functional Tra protein is only produced in females (TraF), where it specifies most aspects of sexual differentiation and development [6163]. When TraF is expressed in males, it is sufficient to induce the development of female-specific traits [64]. It has been previously shown that expression of the TraF transgene alters sex-specific gene expression. For example, Hudry et al [16] demonstrated that expression of the TraF transgene in intestinal progenitors in an otherwise tra null female was sufficient to restore female-specific isoform expression of the tra gene. Moreover, there is an extensive body of literature documenting how targeted expression of the TraF transgene alters sex-specific traits on the single cell level in terms of metabolism, gene expression, physiology, and appearance [16,6567].

To control for differences in the lymph gland due to variation in the genetic background, we analysed flies heterozygous for the TraF construct (TraF/+) and flies heterozygous for the Gal4 driver (Gal4/+) in addition to the experimental group of flies having both the Gal4 and TraF transgene (Gal4/TraF). We then compared males and females from each of the two control groups as well as the experimental group. This meant we were comparing 6 different genotypes to each other, which required us to use a two-way ANOVA, post-hoc Tukey’s test (see methods) to ask if any differences we observed were statistically significant. This test analyzes the significance of changes between groups and provides a “sex:genotype interaction constant” to determine whether the data supported the existence of sex differences between males and females under the experimental treatment.

When we feminized post-mitotic neurons using elav-Gal4, there was no significant effect of genetic background on overall lymph gland size, as males or females of both TraF and elav-Gal4 control flies had a similar number of cells in their lymph gland compared to each other or the experimental group (Fig 3A-3B). Moreover, using these controls suggested that CNS feminization had no significant impact on lymph gland size. Indeed, analysing the sex:genotype interaction constant (Table 1) showed that sex differences in the total number of cells in male and female lymph glands were not altered by feminization of the CNS. Similarly, sex differences in the crystal cells or progenitor numbers did not appear to change upon feminization of the CNS, a conclusion that was supported by analysis of the sex:genotype interaction constant (Fig 3E-3H and 3I-3L, respectively; Table 1). To confirm the findings observed when elav-Gal4 we repeated this analysis with another neuronal driver with a more restricted pattern of distribution, C2-Gal4 [68] and found similar results to those obtained with elav-gal4 (S5 Fig). Taken as a whole, since the effects we saw upon feminization of the CNS were not statistically significant we failed to find evidence that sex differences in the lymph gland were mediated by the CNS.

Fig 3. Feminizing the CNS.

Fig 3

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test for: elav-Gal4 control females (n = 19), elav-Gal4 > TraF females (n = 21), UAS TraF control females (n = 27), elav-Gal4 control males (n = 18), elav-Gal4 > TraF males (n = 18), UAS TraF control males (n = 21). The genotype:sex interaction constant was not significant (p = 0.8059). (C) Representative image of elav-Gal4 control female stained with ToPro. (C’) Representative image of elav-Gal4 control male stained with ToPro. (D,D’) Representative image of elav-Gal4;domeMESO GFP > UAS TraF female (D) and male (D’) stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test for: elav-Gal4 control females(n = 19), elav-Gal4 > TraF females(n = 21), UAS TraF control females(n = 18), elav-Gal4 control males(n = 18), elav-Gal4 > TraF males(n = 18), UAS TraF control males(n = 24) The genotype:sex interaction constant was not significant (p = 0.8966). (G, G’) Representative image of elav-Gal4 control female (G) and male (G’) stained with Hnt. (H, H’) Representative image of elav-Gal4;domeMESO GFP > UAS TraF female (H) and male (H’) stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: elav-Gal4 control females (n = 19), elav-Gal4 > TraF females(n = 21), UAS TraF control females(n = 27), elav-Gal4 control males (n = 18), elav-Gal4 > TraF males (n = 18), UAS TraF control males (n = 21) The genotype:sex interaction constant was not significant (p = 0.0542). (K, K’) Representative image of elav-Gal4 control female (K) and male (K’), expressing GFP in domeMESO+ cells. (L, L’) Representative image of elav-Gal4;domeMESO GFP > UAS TraF female (L) and male (L’), expressing GFP in domeMESO+ cells. **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars indicate 95% CI.

Table 1. Interaction constants for feminization experiments. Sex:Genotype interaction constants derived from two-way ANOVA, post-hoc Tukey’s test performed on data from Figs 3-6 (see methods).

Nuclei Crystal cells Progenitors
Feminized CNS (Fig 3) 0.8059 0.8966 0.0542
Feminized FB (Fig 4) 0.7379 0.7910 0.0045*
Feminized Progenitors (Fig 5) 0.0379* 0.8740 0.0069*
Feminized Niche (Fig 6) 0.0139* 0.0022* 0.0529

* denotes a significant interaction constant (p < 0.05).

We find no evidence that sex differences in the lymph gland are mediated by the fat body

Given that systemic signals from the fat body can also influence cell and body growth [60,69], we asked whether the sexual identity of this key organ played a role in mediating sex differences in the lymph gland. To this end, we feminized the fat body in genetically male flies using the TraF transgene and studied how this impacted individual cell population or overall organ size in the lymph gland. As we did for the CNS feminization experiments, we compared experimental groups of flies having both the R4-Gal4 and TraF transgene (R4-Gal4/TraF) to control flies heterozygous for either the TraF construct (TraF/+) or the Gal4 driver (R4-Gal4/+). We then performed statistical analysis by calculating the sex:genotype interaction constant (Table 1) to determine if any sex differences in the total number of cells, crystal cells, or progenitors in male and female lymph glands were altered by feminization of the fat body in males.

Our control experiments showed that in the genetic background of R4-Gal4, the driver we employed for expression in the fat body, the overall size of the lymph gland was smaller than other backgrounds (Fig 4A). However, since this effect was seen in both males and females it did not impact our interpretation. In particular, we found that feminization of the fat body had no significant impact on size differences between male and female lymph glands (Fig 4A-4D and Table 1). In contrast to what was observed for overall organ size, crystal cell numbers were higher in lymph glands of the experimental group compared to TraF and R4-Gal4 controls for both males and females. Nonetheless, despite this increase, we found no significant impact on sex differences in crystal cell numbers upon fat body feminization, as the increase was observed in both males and females (Fig 4E-4H and Table 1). When progenitor numbers were analysed, we observed a statistically significant increase in their number in the background of the TraF transgene (Fig 4I). Nonetheless, there was no clear impact on sex differences in progenitor numbers (Fig 4I-4L and Table 1). Taken as a whole, our data and statistical analysis supported the interpretation that sex differences in overall size, progenitor number, and crystal cell numbers were not mediated by the fat body.

Fig 4. Feminizing the fat bodies.

Fig 4

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: R4-Gal4 female control (n = 22), R4-Gal4 feminized females (n = 32), UAS TraF control females (n = 27), R4-Gal4 control males (n = 21),R4-Gal4 feminized males (n = 31), UAS TraF control males (n = 21). The genotype:sex interaction constant was not significant (p = 0.7379). (C, C’) Representative image of R4-Gal4 control female (C) and male (C’) stained with Topro. (D) Representative image of R4-Gal4;domeMESO GFP < UAS TraF feminized female stained with ToPro. (D’) Representative image of R4-Gal4;domeMESO GFP < UAS TraF feminized male stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: R4-Gal4 control (n = 22), R4-Gal4 feminized females (n = 32), UAS TraF control (n = 18), R4-Gal4 control males (n = 25), R4-Gal4 feminized males (n = 31), UAS TraF control males (n = 24). The genotype:sex interaction constant was no significant (p = 0.7910). (G, G’) Representative image of R4-Gal4 control female (G) and male (G’) stained with Hnt. (H) Representative image of R4-Gal4;domeMESO GFP x UAS TraF feminized female stained with Hnt. (H’) Representative image of R4-Gal4;domeMESO GFP x UAS TraF feminized male stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: R4-Gal4 control females (n = 22), R4-Gal4 feminized females (n = 32), UAS TraF control females(n = 27), R4-Gal4 control males (n = 21), R4-Gal4 feminized males (n = 31), UAS TraF control males(n = 21). The genotype:sex interaction constant was significant (p = 0.0045). (K, K’) Representative image of R4-Gal4 control female (K) and male (K’), expressing GFP in domeMESO+ cells. (L) Representative image of R4-Gal4;domeMESO GFP x UAS TraF feminized female, expressing GFP in domeMESO+ cells. (L’) Representative image of R4-Gal4;domeMESO GFP x UAS TraF feminized male, expressing GFP in domeMESO+ cells.**** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars indicate 95% CI.

We find no evidence that sex differences in the lymph gland are mediated by the core progenitors

Since we did not uncover compelling evidence for a role of systemic signals from the CNS or the fat body in mediating sex differences in the lymph gland we shifted our focus to lymph gland specific mechanisms. We asked whether the identity of the blood progenitors themselves controlled sex differences. To test this hypothesis, we feminized the core blood progenitors in genetically male flies using the TraF transgene and studied how this impacted overall size as well as the size of individual cell populations in the lymph gland. As before, we compared experimental group flies to flies heterozygous for either the TraF construct (TraF/+) or the Gal4 driver (tep4-Gal4/+) and performed statistical analysis by determining the sex:genotype interaction constant (Table 1). While we noted that the magnitude of sex differences in lymph gland parameters in the tep4-Gal4 control was not as large as in other strains, this was not unexpected given known effects of genetic background on sex difference in size-related traits [67]. Because we still observed a strong female bias in these parameters in tep4-Gal4, we went ahead and performed our analysis as with other strains.

Our analysis revealed significant values for sex:genotype interaction constant for the overall lymph size as well as for progenitor numbers but not for crystal cell numbers (Fig 5A-5D and 5E-5H, respectively; Table 1). However, a closer look revealed that changing the sexual identity of core blood progenitors in genetically male flies did not in fact significantly impact lymph gland size (Fig 5A). Specifically, we observe no differences from controls in terms of lymph gland size in either feminized males, or females overexpressing TraF. This meant we could not draw any relevant conclusions from these experiments. In the case of the core progenitors, the change in sex differences was the result of a decrease in total progenitor cell counts in females with core progenitor-specific TraF expression, while there was no significant impact on progenitor numbers in feminized males (Fig 5I-5L and Table 1). Since the elimination of sex differences resulted from changes in the number of progenitors in females, rather than from feminization of male progenitors, the results of this experiment are difficult to interpret conclusively. To confirm these findings, we repeated this set of experiments using a more general progenitor driver, domeMESO gal4. Unlike the tep4-gal4 driver, which is restricted to core progenitors, the domeMESO gal4 construct allowed us to feminize the entire progenitor pool in males. The results of this analysis (S6 Fig) were very similar to, and confirmed the results obtained with the tep4gal4 driver. Taken as a whole, our data does not conclusively support or disprove an interpretation where feminizing lymph gland core progenitors impacts lymph gland size, crystal number or total progenitor numbers.

Fig 5. Feminizing the progenitors.

Fig 5

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: tep4-Gal4 control females (n = 22), tep4-Gal4 feminized females (n = 26), UAS TraF control females (n = 27), tep4-Gal4 control males (n = 28), tep4-Gal4 feminized males (n = 19), UAS TraF control males (n = 21). The genotype:sex interaction constant was significant (p = 0.0379). (C, C’) Representative image of tep4-Gal4 control female (C) and male (C’) stained with Topro. (D, D’) Representative image of tep4-Gal4;domeMESO GFP < UAS TraF feminized female (D) and male (D’) stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: tep4-Gal4 control females (n = 22), tep4-Gal4 feminized females (n = 26), UAS TraF control females (n = 18), tep4-Gal4 control males (n = 28), tep4-Gal4 feminized males (n = 19), UAS TraF control males (n = 24). The genotype:sex interaction constant was not significant (p = 0.8740). (G) Representative image of tep4-Gal4 control female stained with Hnt. (G’) Representative image of tep4gal4 control male stained with Hnt. (H) Representative image of tep4-Gal4;domeMESO GFP x UAS TraF feminized female stained with Hnt. (H’) Representative image of tep4-Gal4;domeMESO GFP x UAS TraF feminized male stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: tep4-Gal4 control females (n = 22), tep4-Gal4 feminized females (n = 26), UAS TraF control females (n = 27), tep4-Gal4 control males (n = 28), tep4-Gal4 feminized males (n = 19), UAS TraF control males (n = 21). The genotype:sex interaction constant was significant (p = 0.0069) (K) Representative image of tep4-Gal4 control female, expressing GFP in domeMESO+ cells. (K’) Representative image of tep4-Gal4 control male, expressing GFP in domeMESO+ cells. (L) Representative image of tep4-Gal4;domeMESO GFP x UAS TraF feminized female, expressing GFP in domeMESO+ cells. (L’) Representative image of tep4-Gal4;domeMESO GFP x UAS TraF feminized male, expressing GFP in domeMESO+ cells. **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars indicate 95% CI.

Some sex differences in the lymph gland are mediated by the PSC

The PSC has an established role in orchestrating the behaviour of different cell types in the lymph gland and is therefore a candidate for mediating sex differences [3941,70]. Intriguingly, feminization of the PSC in males, using collier-Gal4, induced an increase in the number of cells in the lymph gland which led, for the most part, to the elimination of sex differences in size between females and PSC-feminized males (Fig 6A-6D and Table 1). A similar effect was seen for crystal cell numbers, which were higher in PSC-feminized males and resembled control females (Fig 6E-6H and Table 1). Thus, the sex difference in both overall lymph gland size and crystal cell number was eliminated due to a male-specific increase in these parameters with TraF expression (sex:genotype interaction p = 0.0139 and 0.0022, respectively; two-way ANOVA with post-hoc Tukey’s test).

Fig 6. Feminizing the PSC.

Fig 6

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4 feminized females (n = 16), UAS TraF control females (n = 27), collier-Gal4 control males(n = 31), collier-Gal4 feminized males(n = 20), UAS TraF control males (n = 21). The genotype:sex interaction constant was significant (p = 0.0139). (C, C’) Representative image of collier-Gal4 control female (C) and male (C’) stained with Topro. (D) Representative image of collier-Gal4;domeMESO GFP < UAS TraF feminized female stained with ToPro. (D’) Representative image of collier-Gal4;domeMESO GFP < UAS TraF feminized male stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 20), collier-Gal4 feminized females (n = 16), UAS TraF control females (n = 18), collier-Gal4 control males (n = 29), collier-Gal4 feminized males (n = 21), UAS TraF control males (n = 24). The genotype:sex interaction constant was significant (p = 0.0022). (G, G’) Representative image of collier-Gal4 control female (G) and male (G’) stained with Hnt. (H) Representative image of collier-Gal4;domeMESO GFP x UAS TraF feminized female stained with Hnt. (H’) Representative image of collier-Gal4;domeMESO GFP x UAS TraF feminized male stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4 feminized females (n = 16), UAS TraF control females (n = 27), collier-Gal4 control males (n = 31), collier-Gal4 feminized males (n = 20), UAS TraF control males (n = 21) and collier-Gal4 feminized males (p = 0.9910). The genotype:sex interaction constant was not significant (p = 0.0529). (K, K’) Representative image of collier-Gal4 control female (K) and male (K’), expressing GFP in domeMESO+ cells. (L) Representative image of collier-Gal4;domeMESO GFP x UAS TraF feminized female, expressing GFP in domeMESO+ cells. (L’) Representative image of collier-Gal4;domeMESO GFP x UAS TraF feminized male, expressing GFP in domeMESO+ cells.**** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bar indicates 95% CI.

In contrast to overall size or crystal cell numbers, there was a significant decrease in progenitor cell counts in females with no effect in males (Fig 6I-6L). This effect was similar between the sexes as the sex:genotype interaction was not significant (p = 0.0529; two-way ANOVA). Nonetheless, our data and statistical analysis did support the interpretation that sex differences in overall lymph gland size and crystal cell numbers were mediated, at least in part, by the PSC.

Sex differences in crystal cell number are mediated by insulin signaling in the PSC

Insulin signaling is known to be an important mediator of sex differences in size and tissue growth [7174]. Insulin signaling is also known to be active in the PSC in the lymph gland to regulate hematopoiesis [50,51]. Based on these observations we hypothesized that insulin signaling, in the PSC, was important in mediating sex differences in the lymph gland. For these experiments we used collier-Gal4 to express either an RNAi to knock down the insulin receptor (Fig 7) or a constitutively active version of the insulin receptor (Fig 8). Both of the lines we used have been used repeatedly in the past and their effectiveness at modifying InR activity is well established [75].

Fig 7. Knocking down insulin signaling in the PSC.

Fig 7

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4>InR RNAi females (n = 27), UAS InR RNAi females (n = 26), collier-Gal4 control males (n = 31), collier-Gal4>InR RNAi males (n = 21), UAS InR RNAi control males (n = 30). The sex:genotype interaction constant was not significant (p = 0.0931). (C) Representative image of +> UAS InR RNAi control females stained with ToPro. (C’) Representative image of collier-Gal4 > UAS InR RNAi female stained with ToPro. (D) Representative image of +> UAS InR RNAi control male stained with ToPro, (D’) Representative image of collier-Gal4 > UAS InR RNAi male stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. A two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 20), collier-Gal4>InR RNAi females (n = 25), UAS InR RNAi females (n = 26), collier-Gal4 control males (n = 30), collier-Gal4>InR RNAi males (n = 21), UAS InR RNAi control males (n = 30). The sex:genotype interaction constant was significant (p < 0.0001). (G) Representative image of +> UAS InR RNAi control females stained with Hnt. (G’) Representative image of collier-Gal4 > UAS InR RNAi female stained with Hnt. (H) Representative image of +> UAS InR RNAi control male stained with Hnt (H’) Representative image of collier-Gal4 > UAS InR RNAi male stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. A two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4>InR RNAi females (n = 27), UAS InR RNAi females (n = 26), collier-Gal4 control males (n = 31), collier-Gal4>InR RNAi males (n = 21), UAS InR RNAi control males (n = 30). The genotype:sex interaction constant was not significant (p = 0.5419). (K) Representative image of +> UAS InR RNAi control females expressing GFP in domeMESO+ cells. (K’) Representative image of collier-Gal4 > UAS InR RNAi female expressing GFP in domeMESO+ cells. (L) Representative image of +> UAS InR RNAi control male expressing GFP in domeMESO+ cells. (L’) Representative image of collier gal4 > UAS InR RNAi male expressing GFP in domeMESO+ cells.**** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bar indicates 95% CI.

Fig 8. Constitutively activating insulin in the PSC.

Fig 8

(A-B) Raw cell counts for total number of nuclei, stained with ToPro. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4 > Ca InR females (n = 30), UAS Ca InR control females (n = 25), collier-Gal4 control males (n = 31), collier-Gal4 > Ca InR males (n = 20), UAS Ca InR control males (n = 21). The genotype:sex interaction constant was no significant (p = 0.6852). (C) Representative image of +> UAS Ca InR control females stained with ToPro. (C’) Representative image of collier-Gal4 > UAS Ca InR female stained with ToPro. (D) Representative image of +> UAS Ca InR control male stained with ToPro, (D’) Representative image of collier-Gal4 > UAS Ca InR male stained with ToPro. (E-F) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 20), collier-Gal4 > Ca InR females (n = 27), UAS Ca InR females (n = 25), collier-Gal4 control males (n = 30), collier-Gal4 > Ca InR males (n = 20), UAS Ca InR control males (n = 21). The genotype:sex interaction constant was significant (p < 0.0001). (G) Representative image of +> UAS Ca InR control females stained with Hnt. (G’) Representative image of collier-Gal4 > UAS Ca InR female stained with Hnt. (H) Representative image of +> UAS Ca InR control male stained with Hnt (H’) Representative image of collier-Gal4 > UAS Ca InR male stained with Hnt. (I-J) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: collier-Gal4 control females (n = 28), collier-Gal4 > Ca InR females (n = 30), UAS Ca InR control females (n = 25), collier-Gal4 control males (n = 31), collier-Gal4 > Ca InR males (n = 20), UAS Ca InR control males (n = 21). The genotype:sex interaction constant was not significant (p = 0.7455). (K) Representative image of +> UAS Ca InR control females expressing GFP in domeMESO+ cells. (K’) Representative image of collier-Gal4 > UAS Ca InR female expressing GFP in domeMESO+ cells. (L) Representative image of +> UAS Ca InR control male expressing GFP in domeMESO+ cells. (L’) Representative image of collier-Gal4 > UAS Ca InR male expressing GFP in domeMESO+ cells.**** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bar indicates 95% CI.

We found that PSC-specific reduction in insulin signaling by expression of InR-RNAi led to an increase in the number of cells in male lymph glands, but not female lymph glands (Fig 7A-7D). However, the magnitude of the effect was not statistically significant between the sexes (sex:genotype p = 0.0931; two-way ANOVA; Table 2). In comparison, crystal cell numbers exhibited a more dramatic effect, as their number was greater in experimental group males in which InR was knocked down in the PSC than in females of comparable genotype (Fig 7E-7H). Importantly, we observed a significant sex:genotype interaction and the magnitude of the effect was greater in males than in females, which eliminated the sex difference in this trait (sex:genotype p < 0.0001, Table 2). Analysis of progenitor numbers following InR knockdown in the PSC did not provide statistically significant support for changes in sex differences in this trait (Fig 7I-7L) (sex:genotype p = 0.5789; Table 2).

Table 2. Interaction constants for insulin modulation. Sex:Genotype interaction constants derived from two-way ANOVA, post-hoc Tukey’s test performed on data from Figs 7-8 (see methods).

Nuclei Crystal cells Progenitors
InR RNAi (Fig 7) 0.0931 <0.0001* 0.5789
Ca InR (Fig 8) 0.6852 <0.0001* 0.7455

* denotes a significant interaction constant (p < 0.05).

Analysis of PSC-specific insulin pathway activation via expression of Ca-InR revealed a similar trend. PSC-specific expression of Ca-InR did not greatly alter the number of cells in either male or female lymph glands and consequently there was no statistically significant impact on sex differences in organ size between females and males (Fig 8A-8D) (sex:genotype p = 0.6852; Table 2). In contrast, crystal cell numbers were decreased by PSC specific activation of insulin signaling in females, which resulted in a statistically significant impact leading to an elimination of sex differences (Fig 8E-8H) (sex:genotype p < 0.0001; Table 2). Similar to overall lymph gland size, progenitor numbers were not impacted by PSC specific insulin pathway activation in either males or females and consequently there did not appear to be a significant reduction in sex differences (Fig 8I-8L) (sex:genotype p = 0.7455; Table 2).

Based on the two sets of experiments, utilizing downregulation or hyperactivation of the insulin receptor in the PSC we do not find conclusive support for a function of the insulin pathway in the PSC in mediating sex differences in overall lymph gland size or progenitor numbers. However, there was robust statistical support for the finding that the insulin pathway in the PSC mediates sex differences in crystal cell number. We note that since we did not assess InR expression levels upon TraF overexpression in the PSC it is possible that pathways other than insulin may contribute to sex differences in crystal cell number. In this regard it is encouraging to that there is a similar fold-change in crystal cell number (~1.75) upon either TraF overexpression or upon InR knockdown in the PSC which argues that the Insulin pathway is a major contributor to sex differences. Nonetheless, further evidence confirming a change in signaling downstream of InR-RNAi and Ca-InR expression would be needed to substantiate this conclusion further.

Sex-differences are observed in the cellular immune response following infection

Previous studies in adult Drosophila identified sex-specific differences in the immune response to infection that led to variation in survival rates. Intriguingly, these differences appeared to vary substantially based on the strain of bacteria used for infection [31]. We analysed the cellular immune response in males and females of wild-type (Canton-S) exposed to two different strains of bacteria that are known to activate the immune response in flies, Escherichia coli (E. coli) and Pectobacterium carotovorum (P. carotovorum; previously known as Erwinia carotovora carotovora, or Ecc15) [73,75](see methods). These strains were chosen because they have been shown to act in a sex-specific manner to control behaviour in adult flies [31,7678]. We applied a feeding-based infection protocol, based on previous findings in Sawala et al [79] showing that feeding amount was proportional to body size in males and females meaning their relative food consumption per weight was similar. Infection by feeding with E.coli showed a sex-specific increase in organ size and crystal cell count in females, but not in males (Fig 9A-9C and 9D-9F and Table 3). In comparison, neither sex showed an increase in progenitor count (Fig 9G-9I and Table 3), while both sexes showed an increase in plasmatocyte count upon infection (Fig 9J-9L and Table 3). Infection with P. carotovorum resulted in a significant increase in crystal cell numbers in females but not in males (Fig 10D-10F and Table 3). We found our data were not normally-distributed and consequently used non-parametric tests to determine whether there was a sex:treatment interaction for the effect of Ecc infection on crystal cell number. Despite the fact that there is an apparent female-biased effect, our non-parametric test still did not detect a significant sex:treatment interaction. Specifically, in two types of non-parametric two way ANOVA, the Schreier-Ray-Hare test and an Aligned Rank Transform test, we obtained P values consistent with an insignificant interaction (p = 0.1491 and p = 0.599, respectively). Because the sex:treatment interaction was not significant, potentially due to a variation in the number of female crystal cells, we cannot conclude that there was a sex-biased effect of the infection on crystal cell number. Further experiments will therefore be important in resolving this question. In addition, overall organ size, progenitor numbers, and plasmatocyte numbers were not impacted by infection in either males or females (Fig 10A-10C, 10G-10I, and 10J-10L and Table 3). Taken together these data show that for E. coli, organ size and crystal cell production following infection was differentially regulated between male and female fly larvae. Moreover, analysis of infection with P. carotovorum showed that the magnitude or even the existence of sex-differences in the response to infection may vary depending on the bacterial strain used.

Fig 9. Infection with E. Coli.

Fig 9

(A) Raw cell counts for total number of nuclei, stained with ToPro, in domeMESO GFP x CantonS flies both uninfected (female n = 33, male n = 26) and infected with E.coli bacteria (female n = 23, male n = 25). Sex:treatment interaction constant was significant (p = 0.0076). (B, B’) Representative image of an uninfected (B) and infected (B’) female lymph gland stained with ToPro. (C, C’) Representative image of uninfected (C) and infected (C’) male lymph gland stained with ToPro. (D) Raw cell counts for total number of crystal cells in domeMESO GFP x CantonS flies both uninfected (female n = 33, male n = 26) and infected with E.coli bacteria (female n = 23, male n = 25). Sex:treatment interaction constant was significant (p < 0.0001). (E, E’) Representative image of an uninfected (E) and infected (E’) female lymph gland stained with Hnt. (F, F’) Representative image of an uninfected (F) and infected (F’) male lymph gland stained with Hnt. (G) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells, in domeMESO GFP x CantonS flies both uninfected (female n = 29, male n = 23) and infected with E.coli bacteria (female n = 20, male n = 22). Sex:treatment interaction constant was not significant (p = 0.9293). (H, H’) Representative image of an uninfected (H) and infected (H’) female lymph gland expressing GFP in domeMESO+ cells. (I, I’) Representative image of an uninfected male (I) and infected (I’) lymph gland expressing GFP in domeMESO+ cells. (J) Raw cell counts for total number of plasmatocytes, stained with P1, in domeMESO GFP x CantonS flies both uninfected (female n = 24, male n = 27) and infected with E.coli bacteria (female n = 25, male n = 18). Sex:treatment interaction constant was not significant (p = 0.7160). (K, K’) Representative image of an uninfected (K) and infected (K’) female lymph gland stained with P1. (L, L’) Representative image of an uninfected (L) and infected (L’) male lymph gland stained with P1. All quantification done using a two-way ANOVA, post-hoc Tukey’s test. **** indicates P< < 0.0001, *** indicates P< < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bar indicates 95% CI.

Table 3. Interaction constants for infection. Sex:treatment interaction constants derived from two-way ANOVA, post-hoc Tukey’s test performed on data from Figs 9-10 (see methods).

Nuclei Crystal cells Progenitors Plasmatocytes
E. coli 0.0076* <0.0001* 0.9293 0.7160
P. carotovorum 0.3380 0.1627 0.0981 0.7884

* denotes a significant interaction constant (p < 0.05).

Fig 10. Infection with P.carotovorum.

Fig 10

(A) Raw cell counts for total number of nuclei, stained with ToPro, in domeMESO GFP x CantonS flies both uninfected (female n = 33, male n = 26) and infected with P. carotovorum bacteria (female n = 19, male n = 19). Sex:treatment interaction constant was not significant (p = 0.3380) (B, B’) Representative image of an uninfected (B) and infected (B’) female lymph gland stained with ToPro. (C) Representative image of uninfected (C) and infected (C’) male lymph gland stained with ToPro. (D) Raw cell counts for total number of crystal cells, stained with Hnt, in domeMESO GFP x CantonS flies both uninfected (female n = 33, male n = 26) and infected with P.carotovorum bacteria (female n = 19, male n = 19). Sex:treatment interaction constant was not significant (p = 0.1627). (E, E’) Representative image of an uninfected (E) and infected (E’) female lymph gland stained with Hnt. (F, F’) Representative image of an uninfected (F) and infected (F’) male lymph gland stained with Hnt. (G)Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells, in domeMESO GFP x CantonS flies both uninfected (female n = 29, male n = 23) and infected with P. carotovorum bacteria (female n = 19, male n = 19). Sex:treatment interaction constant was not significant (p = 0.0981). (H, H’) Representative image of an uninfected (H) and infected (H’) female lymph gland expressing GFP in domeMESO+ cells. (I, I’) Representative image of an uninfected (I) and infected (I’) male lymph gland expressing GFP in domeMESO+ cells. (J) Raw cell counts for total number of plasmatocytes, stained with P1, in domeMESO GFP x CantonS flies both uninfected (female n = 24, male n = 27) and infected with P. carotovorum bacteria (female n = 22, male n = 17). Sex:treatment interaction constant was significant (p = 0.7884). (K) Representative image of an uninfected female lymph gland stained with P1. (K’) Representative image of an infected female lymph gland stained with P1. (L) Representative image of an uninfected male lymph gland stained with P1. (L’) Representative image of an infected male lymph gland stained with P1. All quantification done using a one-way ANOVA, post-hoc Tukey’s test. **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bar indicates 95% CI.

Discussion

Our work establishes the Drosophila larva as a model for analysing sex-based differences in cellular immunity. In this regard we build upon an increasing body of evidence that multiple aspects of innate immunity in adult Drosophila exhibit striking sex-based variation [2933,7780]. We find that sex impacts the various cell types found in the lymph gland to different extents under both homeostatic or infection conditions, and that there are distinct mechanisms that control how sex differences are established in the various cell types. This supports a more nuanced and complex role for sex in regulating hematopoiesis beyond a simple generalized increased tissue size and cell number [74,81]. This idea is further supported by single-cell RNA-Seq that uncovered pervasive and wide-ranging sex-differences at the level of gene expression across cell types in the lymph gland. Moreover, we found that the PSC, and more specifically insulin signaling from the PSC, mediated some sex differences but that there are other mechanisms in place since we were not able to mechanistically account for all the variance between males and females. Finally, in line with previous findings of sex-differences in the ability to survive infection in adults [27,2933] we find sex differences in the production of cellular immune response components in larva that was elicited by bacterial infection. Moreover, and consistent with previous findings [27,2933], sex differences in the cellular immune response differed depending on the bacterial strain used for infection, indicating a complex relationship between sex, immunity, and infection. Taken together our work not only functions as an initial characterization of baseline sex-differences in fly hematopoiesis and in cellular immunity, but also identifies important areas for future exploration.

Our analysis of lymph gland single-cell RNA-Seq (scRNA-Seq) data shows significant differences in gene expression across multiple male and female cell types. These differences are not solely confined to genes involved in sex determination and X chromosome dosage compensation. We also observed sex-based expression differences in genes that have been implicated in hematopoiesis and blood cell function. Therefore, we hypothesize that some of the genes we found to be enriched in male or female cell types may be involved in generating the sex-specific hematopoietic phenotypes observed in lymph glands in this study. For example, we found that manipulating insulin signaling in the PSC in males, but not females, leads to changes in crystal cell differentiation. Intriguingly, crystal cells exhibit a more pronounced level of sex-differences compared to other cell types in the lymph glands, beyond what can be simply accounted for by body size. With that added context it is possible that the sex-based differences in crystal cell numbers represent a unique difference in developmental outcome rather than a difference that is purely based on body size. These data also align well with the scRNA-Seq data, which shows that the insulin-like peptide dILP-6/Ilp6 is specifically enriched in male PSC cells and male crystal cells (Fig 2B). Future study is required to test if enrichment of dILP-6/Ilp6 expression in male PSC cells is an underlying mechanism contributing to this phenotype. Moreover, gene expression differences in our scRNA-Seq data suggest interesting hypotheses about the potential causes underlying the different infection phenotypes observed in male and female lymph glands. For instance, we observed enrichment in the Toll and Imd signaling pathways in female progenitors, intermediate progenitors, and plasmatocytes compared to their male counterparts. These cell types can undergo cell division and serve as precursors for crystal cell differentiation [82,8386] Further study is needed to understand whether this sex-specific difference in gene expression in these cell types is required for the increase in crystal cells and lymph gland size observed in females after infection.

Although the existence of sex differences in innate immunity in Drosophila adults is well established [27,29,31], it is not yet standard practice to consider sex as a variable in studies that focus on the larval lymph gland. Based on our findings, we believe there is a substantial argument that in the future it should become a standard practice to consider sex as a key variable for all phenotypic characterization of the lymph gland. Although the common practice in the field of normalizing the reported cell counts to lymph gland size would, in general, correct for sex-differences in size, it might not do so in all instances. Moreover, previous genetic experiments that allowed manipulations in only one sex, for example due to the availability of certain drivers only on the X-chromosome, may need to be revisited and assayed for both sexes. We therefore suggest that data should be reported separately for both sexes. Although some aspects of larval immunity, such as plasmatocyte numbers, may not vary greatly between males and females under normal conditions, differences might become apparent under specific experimental conditions. Our study did not aim to exhaustively characterize all sex-based differences in the lymph gland, which we suspect vary considerably based on the genetic background and experimental conditions. Rather our aim was to establish that sex differences are pervasive in the lymph gland and to provide some insight into the mechanisms that are responsible for these differences. We predict that as more researchers in the field separately report data for males and females for various lymph gland phenotypes, the number of documented sex differences will greatly expand. Moreover, the emergence of sex-differences, and exploring the possibility that differences already exist in embryonically derived hemocytes should prove an exciting area for future research.

Our analysis argues for an important role for the Drosophila lymph gland niche, the PSC, in at least a subset of sex differences. We did not find conclusive evidence for a role in sex differences for systemic signals that originate from the CNS and the fat body, or from local signals derived from the progenitors. A key limitation of these studies is the lack of completely specific drivers that only, with 100% specificity, drive expression in the tissue they are targeting (such as the CNS or Fat). Moreover, the drivers we use to express in different cell-populations in the lymph gland can be expressed outside of the lymph gland. For example, collier-Gal4 is expressed in the PSC of the lymph gland, but is also expressed in the CNS, wing disc pouch, and sporadically in the lymph gland posterior lobes [87].Coupled with experimental noise and the influence of genetic background this can make interpretation challenging. We therefore sought to be as rigorous as possible in how we interpreted the results and set a high threshold to accept an effect as real. In particular, the thresholds that needed to be met to deem a result as meaningful were ensuring both the multiple comparisons across genotypes as well as the sex:genotype interaction was statistically significant. This cautious approach means that with the availability of better tools in the future we may find more tissues or cell types in the lymph gland are involved in mediating sex-differences. Nonetheless, our results already suggest that juxtacrine signals or perhaps cell autonomous signals play an important mechanistic role in sex differences in hematopoiesis. However, this does not imply the absence of other known types of sex differences that have been demonstrated to exist in flies and that we did not assay for, such as differences in physiology or metabolism [81]. Instead, our work assayed cell numbers, a parameter which is most relevant for immune function. As the repertoire of known sex differences in hematopoiesis grows, which we predict will be the case once separating data by sex becomes the norm in the field, it will be valuable to revisit the role of systemic signals as these are likely to play a part in at least some of these additional processes. Moreover, finding the mechanisms that mediate sex differences in progenitor numbers, which at present remain unknown, will be an important goal of future work.

In adult Drosophila, there are intriguing sex-specific behavioral responses to the presence of bacteria. For example, female flies are less likely to lay eggs in the presence of high levels of bacteria, seen as a protective mechanism designed to avoid egg laying in an environment inhospitable to them [75]. In the larval stage it is less clear what functions sex differences may have. It could be that their role is to set up future differences in the adult, and/or it could be that there is emphasis on preventing infection that could become chronic and harm egg production. The possibility of sex differences in larva impacting the adult immune response is supported by noting that a large portion of adult hemocytes derive from the larval lymph gland [88]. The potential importance of preventing infection in females during larval stages is highlighted by studies showing that infection in adult female flies impacts egg production and/or fecundity [89,90].

Taken as a whole, our work highlights the complex interactions between sex, genotype, and the environment in controlling Drosophila hematopoiesis and immunity. Our phenotypic analysis shows substantial variation across genotypes and environmental conditions in the proportion of different cell populations present in the lymph gland. In some experiments this did not allow us to obtain conclusive findings. However, this variability could represent important individual differences in life history, growth conditions, and environmental conditions between larvae. By accounting for sex as a factor that impacts lymph gland phenotype, it should be possible to reduce variation introduced by mixing data from males and females. This consideration will improve reproducibility and make future analysis more precise and meaningful.

Materials and methods

Fly stocks and genetics

All Drosophila crosses were kept at 25°C and sustained in vials containing a standard cornmeal fly food (recipe from Bloomington Drosophila Stock Center). All lymph gland progenitors were labelled using fluorescent markers tep4-gal4; UAS-GFP or domeMESO GFP. Control larvae in Fig 1 are categorized as w1118 flies crossed to tep4-gal4; UAS GFP. Wildtype larvae in Figs 8-9 are categorized as CantonS flies crossed to domeMESO GFP.

Using the Gal4/UAS system [89], various tissues were feminized by overexpressing sex determination gene transformer (tra), a master regulator of female sexual identity and development [6164,81]. The drivers used were elav-gal4 (CNS) [91], R4-gal4 (fat body) [92], tep4-gal4 (lymph gland progenitors) [93], and collier-gal4 (PSC cells) [94]. These drivers were crossed to domeMESO GFP for controls, and UAS TraF/CyoGFP;domeMESO GFP/TM6 for feminization experiments. A UAS control was also used by crossing UAS TraF/CyoGFP; domeMESO GFP/TM6 to domeMESO GFP.

To control for the possible genetic effects of the domeMesoGFP transgene we confirmed its inclusion had no impact on sex differences in the lymph gland (S7 Fig).

In order to constitutively activate or knockdown insulin receptors in the lymph gland, Ca-InR (RRID: BDSC_8250) and InR RNAi (RRID: BDSC_51518) were crossed to domeMESO GFP as a control, and crossed to PSC cell driver collier-gal4.

Larval lymph gland dissections

Wandering third instar larval lymph glands were dissected in ice-cold 1X Phosphate Buffer Saline (PBS), and then fixed in 4% paraformaldehyde (PFA) for 15 minutes. Samples were then washed in 0.1% PTX (1X PBS with 0.1% Triton X [Thermofisher Scientific, BP 151100]) twice for 5 minutes each, then blocked with 16% Neat Goat Serum (NGS) (ab7481, abcam) for 15 minutes, before being incubated in a primary antibody overnight at 4°C. The following day, samples were washed again twice in 0.1% PTX for 5 minutes each, blocked in 16% NGS for 15 minutes, before being incubated in a secondary antibody for two hours at room temperature. Samples were washed three times in 0.1% PTX for 5 minutes each, and mounted in VECTASHIELD (Vector Laboratories, H-1000, RRID: AB_2336789) with TOPRO3 iodide (ThermoFisher Scientific, T3605; 1:500) in glass bottom mounting dishes (MatTek Corporation, 35 mm, P35G-0–14-C).

Immunohistochemistry

The following primary antibodies were used and diluted in 0.1% PTX: mouse anti-hindsight (1:50, DSHB 1G9, RRID: AB_2617420), mouse anti-Antennapedia (1:25, DSHB 4C3, RRID: AB_528082). The following primary antibodies were used and diluted in 0.1% Tween 20 (1X PBS with 0.1% Tween 20 [Fisher BioReagents, BP337–500]): mouse anti- P1 (1:100, anti-NimC1, a kind gift from Dr. Istvan Ando, Hungarian Academy of Sciences, Hungary).

The following secondary antibody was used and diluted in 0.1% PTX (for Hnt and Antp staining) or 0.1% Tween 20 (for P1 staining): donkey anti-mouse Cy3 (1:400, Jackson Immunoresearch Laboratories, Code: 715-165-150, RRID: AB_2340813) and TOPRO3 iodide (1:800).

Analysis of single-cell RNA-Seq data

Partek Flow software was used for single-cell sequencing analysis. The previously published single-cell data set was used, which includes the same initial data processing parameters for read trimming, quality control, alignment of reads to the Drosophila melanogaster reference genome r6.22, normalization and low input filtration, and exclusion of ribosomal RNA genes [95].

Principal component (PC) analysis (PCA) was completed prior to graph-based clustering. Based on the Scree plot, the first 20 PCs were selected to use as the input for clustering and data visualization tasks. Graph-based clustering was first performed with 50 nearest neighbors (NNs) and resolution (res) of 0.25–0.75 giving 6–9 clusters, with 7 clusters (res = 0.5-0.57) showing the most marked differences in gene expression between clusters. The data was visualized using UMAP with a local neighborhood size of 15, minimal distance of 0.1, Euclidean distance metric, and random generator seed of 0. We used established lymph gland marker genes to identify which cell type each of the graph-based clusters corresponds as done previously [82]. We determined sex by using the expression of two long non-coding RNAs (lncRNAs): lncRNA:roX1, lncRNA:roX2. Cells that are high for expression of both lncRNA:roX1 and lncRNA:roX2 were characterized as males, cells that were low for both were characterized as female, and cells that had high expression for only one of the lncRNAs were characterized as ambiguous and excluded from further analysis.

We used an ANOVA analysis to determine which genes were differentially expressed in males versus female cells. We set a threshold of 1.5-fold enrichment for genes to be considered differentially expressed and discarded genes which were enriched below that threshold. We also used a false-discovery rate (FDR) threshold of less than or equal to 0.0001, discarding any genes which were above that threshold. We took the remaining genes and thus had a list of differentially expressed genes (DEGs) for males and females (S1S4 Files). We then performed a similar analysis comparing male and female cells in each of the graph-based clusters to identify sex differences in specific lymph gland cell types (S1S4 Files).

We then compared the list of DEGs from each cluster to one another and to the DEGs for the lymph gland overall (S10 File). We used the multiple list comparator from molbiotools to compare the lists and generate Venn diagrams to see which genes were uniquely over-expressed in each cluster. We then used g:Profiler’s

g:GOSt tool [96] for gene-set enrichment analysis to find gene ontology terms, KEGG and WP pathways, or transcription factor binding sites associated with the DEGs in each cluster (S5S8 Files). We used these terms to highlight DEGs of particular interest due to their pattern of enrichment in specific male or female cell types, their involvement in blood cell development or disease, and their conservation across species (S9 File).

Infection

An ampicillin resistant, GFP expressing strain of Escherichia coli [93,94](a kind gift from Dr. Bret Finlay, The University of British Columbia, Vancouver, Canada) and Pectobactorium carotovorum (a kind gift from Dr. Edan Foley, University of Alberta, Edmonton, Canada) were grown in LB media and incubated at 37°C and 30°C respectively overnight. Second instar larvae were picked out of food, washed in ddH2O and 70% ethanol, then starved on a polydimethylsiloxane pad for 2 hours before being placed into 4g of fly food with either 200 µl of PBS (control) or 200µL of E.coli or P. carotovorum resuspended in PBS. Vials were then placed back in 25°C for 9 hours and dissected using the protocol described previously.

Imaging and data analysis

All images were acquired on an Olympus FV1000 inverted confocal microscope, using a 40x lens. Image analysis was done using Olympus Fluoview (Ver.1.7c) and MATLAB scripts previously used in Khadiklar, 2017 [93]. Total number of nuclei, prohemocytes and plasmatocytes were determined using this Matlab script. Crystal cells and niche cells were counted manually using the cell counter plugin in ImageJ.

To correct for body size, average weight was taken for males and females of a genotype by collecting 10–12 third instar larvae, weighing them, and dividing total weight by number of larvae weighed. This weight, in milligrams, was then used to correct data points for body size (Fig 1F’-1J’).

Statistics were performed using GraphPad Prism. P values were determined using a two-tailed unpaired t-test, a one way ANOVA with multiple comparisons (Tukey’s test), or a two-way ANOVA multiple comparison (Tukey’s Test). **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. The sample size and statistical method of each analysis were indicated in the figure legends.

A two-way ANOVA (Tukey’s test) was used to determine both p values in multiple comparisons, as well as an overall sex:genotype or sex:treatment interaction value. The multiple comparison significance are shown within the figure, with the exact p values and the interaction value shown in the figure legends.

Supporting information

S1 Movie. Three dimensional UMAP visualization of single-cell sequencing data showing cells from three biological replicate samples (21,157 total cells), each containing a mixed population of lymph gland primary lobes from 5 male and 6 female larvae.

Graph based clusters defining lymph gland cell types (left panel) and expression of the male-specific genes lncRNA:roX1 (middle panel) and lncRNA:roX2 (right panel) visualized on the UMAP. PSC, posterior signaling center; MZ, medullary zone; IZ, intermediate progenitor; proPL, proplasmatocyte; PL, plasmatocyte; CC, crystal cell; X, mitotic cluster.

(MOV)

Download video file (7MB, mov)
S1 File. Anova analysis was used to determine fold change in the number of reads for each gene, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

(PDF)

pgen.1012151.s002.pdf (223.2KB, pdf)
S2 File. Anova analysis was used to determine fold change in the number of reads for each gene in the MZ, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

(PDF)

pgen.1012151.s003.pdf (224.9KB, pdf)
S3 File. Anova analysis was used to determine fold change in the number of reads for each gene in the crystal cells, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

(PDF)

pgen.1012151.s004.pdf (200.3KB, pdf)
S4 File. Anova analysis was used to determine fold change in the number of reads for each gene in the PSC, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

(PDF)

pgen.1012151.s005.pdf (308.4KB, pdf)
S5 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster overall.

(PDF)

pgen.1012151.s006.pdf (167.8KB, pdf)
S6 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the MZ.

(PDF)

pgen.1012151.s007.pdf (157.9KB, pdf)
S7 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the crystal cells.

(PDF)

pgen.1012151.s008.pdf (152.6KB, pdf)
S8 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the PSC.

(PDF)

pgen.1012151.s009.pdf (158.2KB, pdf)
S9 File. A selection of interesting sex-specific DEGs for further study.

These genes were selected for being enriched in one cell type, being broadly conserved across species (including in humans in most cases), and having some connection to blood cell development or disease, or immune cell phenotypes. References are included for each gene detailing the known roles of these genes or their mammalian orthologs in blood cell development, disease, or phenotypes.

(PDF)

pgen.1012151.s010.pdf (83.8KB, pdf)
S10 File. We used the multiple list comparator from molbiotools to compare DEG lists from Table 1 and determine which genes were uniquely overexpressed in each cluster.

We ran this analysis both with and without the ‘overall’ category, which refers to the comparison of total male and female lymph gland cells.

(PDF)

pgen.1012151.s011.pdf (292.4KB, pdf)
S1 Table. Total counts for sex determination genes.

Total number of sex determination genes separated by males and females, as well as total counts per cell.

(PDF)

pgen.1012151.s012.pdf (22.3KB, pdf)
S1 Fig. Differences between collier+ and Antp+ cell counts.

Total cell count for both collier+ PSC cells (expressing GFP through collier-gal4) as well as Antp+ cells (stained with Antp antibody) in males and females. A significant difference was found in females between the two cell types (p = 0.0029). A significant difference was found in males between the two cell types (p = 0.0003).

(TIF)

pgen.1012151.s013.tif (70.5KB, tif)
S2 Fig. Mean Intensity of colliergal4 and tep4gal4 Mean intensity of both collier+ and tep4+ cells measured for both males and females using ImageJ.

(TIF)

pgen.1012151.s014.tif (66.8KB, tif)
S3 Fig. Raw cell counts from main text Fig 1H-1L corrected by dividing each female data point by average total lymph gland nuclei count (main text Fig 1G) and dividing each male data point by average phenotype weight (main text Fig 1G).

(A) Corrected number of PSC cells (Antp+) (female n = 64, male n = 59, p = 0.7819). (B) Corrected number of core progenitors (tep4+) (female n = 64, male n = 59, p = 0.9705). (C) Corrected number of crystal cells (Hnt+) (female n = 25, male n = 19, p = 0.0056). (D) Corrected number of plasmatocytes (P1+) (female n = 30, male n = 22, p = 0.4531). (E) Corrected number total progenitors (domeMESO+) (female = 24, male = 26, p = 0.6048). **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars are 95% CI.

(TIF)

pgen.1012151.s015.tif (94.9KB, tif)
S4 Fig. Crystal cell counts corrected for body and lymph gland size.

(A) Raw cell counts for crystal cells in w1118 x tep4GFP male and female larvae show a significant difference (p < 0.0001). (B) Total cell counts for crystal cells in w1118 x tep4GFP male and female larvae, corrected for body size, show a significant difference (p = 0.0056). (C)Total cell counts for crystal cells in w1118 x tep4GFP male and female larvae, corrected for total lymph gland size (total nuclei count for each lobe corresponding to crystal cell number data point), show a significant difference (p = 0.0011).

(TIF)

pgen.1012151.s016.tif (95.4KB, tif)
S5 Fig. Feminization with c2-gal4 (A-B) Raw cell counts for total number of nuclei, stained with ToPro.

Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 female control (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control females (n = 27), c2-Gal4 control males (n = 21),c2-Gal4 feminized males (n = 16), UAS TraF control males (n = 21). The genotype:sex interaction constant was not significant (p = 0.4208). (C-D) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 control (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control (n = 18), c2-Gal4 control males (n = 21), c2-Gal4 feminized males (n = 16), UAS TraF control males (n = 24). The genotype:sex interaction constant was not significant (p = 0.7396). (E-F) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 control females (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control females(n = 27), c2-Gal4 control males (n = 21), c2-Gal4 feminized males (n = 16), UAS TraF control males(n = 21). The genotype:sex interaction constant was not significant (p = 0.0590).

(TIF)

pgen.1012151.s017.tif (315.1KB, tif)
S6 Fig. domeMESO gal4 based feminization of progenitors.

A) Raw cell counts for total number of nuclei. A 2 way ANOVA, Tukey’s test showed: no significance between domeMESO gal4 control females and domeMESOgal4 feminized females (p = 0.7209), a significant difference between UAS TraF control females and domeMESOgal4 feminized females (p = 0.0005), no significance between domeMESO control males and domeMESO feminized males (p = 0.9949), and no significance between UAS TraF control males and domeMESO feminized males (p = 0.2093). The genotype:sex interaction constant was not significant (p = 0.1876). (B) Raw cell counts for total number of nuclei comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.4752), no significant difference between domeMESO gal4 feminized females and males (p = 0.1425), and a significant difference between UAS TraF control females and males (p < 0.0001). (C) Raw cell counts for total number of crystal cells. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and domeMESO gal4 feminized females (p = 0.2599),no significant difference between UAS TraF control females and domeMESO gal4 feminized females(p > 0.9999), no significant difference between domeMESO gal4 control males and domeMESO gal4 feminized males (p = 0.2422), and no significant difference between UAS TraF control males and domeMESO gal4 feminized males (p = 0.9452). The genotype:sex interaction constant was not significant (p = 0.7756). (D) Raw cell counts for total number of crystal cells comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.1782), no significant difference between domeMESO gal4 feminized females and males (p = 0.3322), and a significant difference between UAS TraF control females and males (p = 0.0032). (E) Raw cell counts for total number of domeMESO+ progenitors. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and domeMESO gal4 feminized females (p > 0.9999), a significant difference between UAS TraF control females and domeMESO gal4 feminized females (p < 0.0001), no significant difference between domeMESO gal4 control males and domeMESO gal4 feminized males (p = 0.9393), and a significant difference between UAS TraF control males and domeMESO gal4 feminized males (p = 0.0001). The genotype:sex interaction constant was significant (p = 0.0252). (F) Raw cell counts for total number of domeMESO+ progenitors comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.5104), no significant difference between domeMESO gal4 feminized females and males(p = 0.1194), and a significant difference between UAS TraF control females and males (p < 0.0001).

(TIF)

pgen.1012151.s018.tif (315.1KB, tif)
S7 Fig. Heterozygous/Homozygous domeMESOGFP.

Heterozygous cross of UAS TraF; + x domeMESOGFP and homozygous cross of UAS TraF;domeMESOGFP x domeMESOGFP, separated by sex. (A) Raw total nuclei count of heterozygous females(n = 17) and homozygous females(n = 16) are shown to have no significant difference (p = 0.2208). (B) Raw total nuclei count of heterozygous males(n = 21) and homozygous males (n = 16) are shown to have no significant difference (p = 0.2259). (C) Significant difference between heterozygous females and males (p = 0.0007), and significant difference between homozygous females and males (p = 0.0067). (D) Raw crystal cell count of heterozygous females (n = 17) and homozygous females (n = 16) are shown to have no significant difference (p = 0.3339). (E) Raw crystal cell count of heterozygous males (n = 21) and homozygous males (n = 16) are shown to have no significant difference (p = 0.6017). (F) Significant difference between heterozygous females and males (p = 0.0463), and significant difference between homozygous females and males (p < 0.0001). (G) Raw domeMESO+ progenitor count of heterozygous females (n = 17) and homozygous females (n = 16) are shown to have no significant difference (p = 0.7122). (H) Raw domeMESO+ progenitor count of heterozygous males (n = 19) and homozygous males (n = 16) are shown to have no significant difference (p = 0.9136). (I) Significant difference between heterozygous females and males (p = 0.0022), and significant difference between homozygous females and males (p = 0.0025).

(PDF)

pgen.1012151.s019.pdf (541.2KB, pdf)
S1 Data. All raw and corrected cell counts for male and female w1118 x tep4 GFP wildtype flies.

(PDF)

pgen.1012151.s020.pdf (79.9KB, pdf)
S2 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 3 (CNS feminization), including both UAS and gal4 controls, and feminized experimental group.

(PDF)

pgen.1012151.s021.pdf (55.3KB, pdf)
S3 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 4 (fat body feminization), including both UAS and gal4 controls, and feminized experimental group.

(PDF)

pgen.1012151.s022.pdf (59.6KB, pdf)
S4 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 5 (domeMESO+ progenitor feminization), including both UAS and gal4 controls, and feminized experimental group.

(PDF)

pgen.1012151.s023.pdf (57.9KB, pdf)
S5 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 6 (PSC feminization), including both UAS and gal4 controls, and feminized experimental group.

(PDF)

pgen.1012151.s024.pdf (58KB, pdf)
S6 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 7 (insulin receptor knockdown in the PSC), including both UAS and gal4 controls, and experimental group.

(PDF)

pgen.1012151.s025.pdf (60KB, pdf)
S7 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 8 (constitutively active insulin receptor in the PSC), including both UAS and gal4 controls, and experimental group.

(PDF)

pgen.1012151.s026.pdf (59.6KB, pdf)
S8 Data. All raw cell counts for total nuclei, crystal cells, domeMESO+ progenitors, and plasmatocytes for Fig 9, including both control and infected males and females with E.coli.

(PDF)

pgen.1012151.s027.pdf (55.7KB, pdf)
S9 Data. All raw cell counts for total nuclei, crystal cells, domeMESO+ progenitors, and plasmatocytes for Fig 10, including both control and infected males and females with P.carotovorum.

(PDF)

pgen.1012151.s028.pdf (55.4KB, pdf)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

o Funding for this study was provided by a grant to G.T. from the Canadian Institutes of Health Research (Project Grant PJT-156277). K.Y.L.H was supported by a 4-Year Doctoral Fellowship from UBC. The funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Arnold AP. A general theory of sexual differentiation. J Neurosci Res. 2017;95(1–2):291–300. doi: 10.1002/jnr.23884 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Arnold AP. Rethinking sex determination of non-gonadal tissues. Curr Top Dev Biol. 2019;134:289–315. doi: 10.1016/bs.ctdb.2019.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fairbairn DJ. Allometry for sexual size dimorphism: patterns and processes. Annu Rev Ecol Evol Syst. 2005;36:51–71. [Google Scholar]
  • 4.Zhang H, Zhang L, He Z. Sex‑specific regulation of growth and muscle development in Drosophila melanogaster. Dev Biol. 2018;442(2):136–47. doi: 10.1016/j.ydbio.2018.02.014 [DOI] [Google Scholar]
  • 5.Bond JE, Cormier TA. Hormonal regulation of sexual dimorphism in body size and tissue growth in Drosophila. Front Physiol. 2020;11:1013. doi: 10.3389/fphys.2020.01013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Capel B. The battle of the sexes. Mech Dev. 2000;92(1):89–103. doi: 10.1016/s0925-4773(99)00327-5 [DOI] [PubMed] [Google Scholar]
  • 7.Hubbard EJ, Greenstein D. The Caenorhabditis elegans gonad: a test tube for cell and developmental biology. Dev Dyn. 2000;218(1):2–22. doi: 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W [DOI] [PubMed] [Google Scholar]
  • 8.Jazin E, Cahill L. Sex differences in molecular neuroscience: from fruit flies to humans. Nat Rev Neurosci. 2010;11(1):9–17. doi: 10.1038/nrn2754 [DOI] [PubMed] [Google Scholar]
  • 9.Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ. 2012;3(1):13. doi: 10.1186/2042-6410-3-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Matson CK, Zarkower D. Sex and the singular DM domain: insights into sexual regulation, evolution and plasticity. Nat Rev Genet. 2012;13(3):163–74. doi: 10.1038/nrg3161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Nef S, Parada LF. Hormones in male sexual development. Genes Dev. 2000;14(24):3075–86. doi: 10.1101/gad.843800 [DOI] [PubMed] [Google Scholar]
  • 12.Sekido R, Lovell-Badge R. Genetic control of testis development. Sex Dev. 2013;7(1–3):21–32. doi: 10.1159/000342221 [DOI] [PubMed] [Google Scholar]
  • 13.Swain A, Lovell-Badge R. Mammalian sex determination: a molecular drama. Genes Dev. 1999;13(7):755–67. doi: 10.1101/gad.13.7.755 [DOI] [PubMed] [Google Scholar]
  • 14.Hughes IA. Minireview: sex differentiation. Endocrinology. 2001;142(8):3281–7. doi: 10.1210/endo.142.8.8406 [DOI] [PubMed] [Google Scholar]
  • 15.Wat LW, Chao C, Bartlett R, Buchanan JL, Millington JW, Chih HJ, et al. A role for triglyceride lipase brummer in the regulation of sex differences in Drosophila fat storage and breakdown. PLoS Biol. 2020;18(1):e3000595. doi: 10.1371/journal.pbio.3000595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hudry B, Khadayate S, Miguel-Aliaga I. The sexual identity of adult intestinal stem cells controls organ size and plasticity. Nature. 2016;530(7590):344–8. doi: 10.1038/nature16953 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mathews KW, Cavegn M, Zwicky M. Sexual Dimorphism of Body Size Is Controlled by Dosage of the X-Chromosomal Gene Myc and by the Sex-Determining Gene tra in Drosophila. Genetics. 2017;205(3):1215–28. doi: 10.1534/genetics.116.192260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Surkova S, Görne J, Nuzhdin S, Samsonova M. Interplay between sex determination cascade and major signaling pathways during Drosophila eye development: Perspectives for future research. Dev Biol. 2021;476:41–52. doi: 10.1016/j.ydbio.2021.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dunn SE, Perry WA, Klein SL. Mechanisms and consequences of sex differences in immune responses. Nat Rev Nephrol. 2024;20(1):37–55. doi: 10.1038/s41581-023-00787-w [DOI] [PubMed] [Google Scholar]
  • 20.Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38. doi: 10.1038/nri.2016.90 [DOI] [PubMed] [Google Scholar]
  • 21.Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15(8):955–9. doi: 10.1038/nm.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J Immunol. 2006;177(4):2088–96. doi: 10.4049/jimmunol.177.4.2088 [DOI] [PubMed] [Google Scholar]
  • 23.Boissier J, Chlichlia K, Digon Y, Ruppel A, Moné H. Preliminary study on sex-related inflammatory reactions in mice infected with Schistosoma mansoni. Parasitol Res. 2003;91(2):144–50. doi: 10.1007/s00436-003-0943-1 [DOI] [PubMed] [Google Scholar]
  • 24.Melgert BN, Oriss TB, Qi Z, Dixon-McCarthy B, Geerlings M, Hylkema MN, et al. Macrophages: regulators of sex differences in asthma?. Am J Respir Cell Mol Biol. 2010;42(5):595–603. doi: 10.1165/rcmb.2009-0016OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178(11):6710–4. doi: 10.4049/jimmunol.178.11.6710 [DOI] [PubMed] [Google Scholar]
  • 26.Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun. 2009;10(5):509–16. doi: 10.1038/gene.2009.12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Belmonte RL, Corbally M-K, Duneau DF, Regan JC. Sexual Dimorphisms in Innate Immunity and Responses to Infection in Drosophila melanogaster. Front Immunol. 2020;10:3075. doi: 10.3389/fimmu.2019.03075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Palmer WH, Medd NC, Beard PM, Obbard DJ. Isolation of a natural DNA virus of Drosophila melanogaster, and characterisation of host resistance and immune responses. PLoS Pathog. 2018;14(6):e1007050. doi: 10.1371/journal.ppat.1007050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chowdhury M, Li C-F, He Z, Lu Y, Liu X-S, Wang Y-F, et al. Toll family members bind multiple Spätzle proteins and activate antimicrobial peptide gene expression in Drosophila. J Biol Chem. 2019;294(26):10172–81. doi: 10.1074/jbc.RA118.006804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Vincent CM, Sharp NP. Sexual antagonism for resistance and tolerance to infection in Drosophila melanogaster. Proc Biol Sci. 2014;281(1788):20140987. doi: 10.1098/rspb.2014.0987 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Duneau DF, Kondolf HC, Im JH, Ortiz GA, Chow C, Fox MA, et al. The Toll pathway underlies host sexual dimorphism in resistance to both Gram-negative and Gram-positive bacteria in mated Drosophila. BMC Biol. 2017;15(1):124. doi: 10.1186/s12915-017-0466-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kutch IC, Fedorka KM. A test for Y-linked additive and epistatic effects on surviving bacterial infections in Drosophila melanogaster. J Evol Biol. 2017;30(7):1400–8. doi: 10.1111/jeb.13118 [DOI] [PubMed] [Google Scholar]
  • 33.Martins NE, Faria VG, Nolte V, Schlötterer C, Teixeira L, Sucena É, et al. Host adaptation to viruses relies on few genes with different cross-resistance properties. Proc Natl Acad Sci U S A. 2014;111(16):5938–43. doi: 10.1073/pnas.1400378111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ma X, Li W, Yu H, Yang Y, Li M, Xue L, et al. Bendless modulates JNK-mediated cell death and migration in Drosophila. Cell Death Differ. 2014;21(3):407–15. doi: 10.1038/cdd.2013.154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kelsey EM, Luo X, Brückner K, Jasper H. Schnurri regulates hemocyte function to promote tissue recovery after DNA damage. J Cell Sci. 2012;125(Pt 6):1393–400. doi: 10.1242/jcs.095323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yu S, Luo F, Jin LH. The Drosophila lymph gland is an ideal model for studying hematopoiesis. Dev Comp Immunol. 2018;83:60–9. doi: 10.1016/j.dci.2017.11.017 [DOI] [PubMed] [Google Scholar]
  • 37.Lan W, Liu S, Zhao L, Su Y. Regulation of Drosophila Hematopoiesis in Lymph Gland: From a Developmental Signaling Point of View. Int J Mol Sci. 2020;21(15):5246. doi: 10.3390/ijms21155246 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sinenko SA, Mandal L, Martinez-Agosto JA, Banerjee U. Dual role of wingless signaling in stem-like hematopoietic precursor maintenance in Drosophila. Dev Cell. 2009;16(5):756–63. doi: 10.1016/j.devcel.2009.03.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pennetier D, Oyallon J, Morin-Poulard I, Dejean S, Vincent A, Crozatier M. Size control of the Drosophila hematopoietic niche by bone morphogenetic protein signaling reveals parallels with mammals. Proc Natl Acad Sci U S A. 2012;109(9):3389–94. doi: 10.1073/pnas.1109407109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Krzemień J, Dubois L, Makki R, Meister M, Vincent A, Crozatier M. Control of blood cell homeostasis in Drosophila larvae by the posterior signalling centre. Nature. 2007;446(7133):325–8. doi: 10.1038/nature05650 [DOI] [PubMed] [Google Scholar]
  • 41.Mandal L, Martinez-Agosto JA, Evans CJ, Hartenstein V, Banerjee U. A Hedgehog- and Antennapedia-dependent niche maintains Drosophila haematopoietic precursors. Nature. 2007;446(7133):320–4. doi: 10.1038/nature05585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Morin-Poulard I, Vincent A, Crozatier M. The Drosophila JAK-STAT pathway in blood cell formation and immunity. JAKSTAT. 2013;2(3):e25700. doi: 10.4161/jkst.25700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Makki R, Meister M, Pennetier D, Ubeda J-M, Braun A, Daburon V, et al. A short receptor downregulates JAK/STAT signalling to control the Drosophila cellular immune response. PLoS Biol. 2010;8(8):e1000441. doi: 10.1371/journal.pbio.1000441 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Mooney RA, Kulas DT, Bleyle LA, Novak JS. The protein tyrosine phosphatase LAR has a major impact on insulin receptor dephosphorylation. Biochem Biophys Res Commun. 1997;235(3):709–12. doi: 10.1006/bbrc.1997.6889 [DOI] [PubMed] [Google Scholar]
  • 45.Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. J Biol Chem. 1996;271(2):748–54. doi: 10.1074/jbc.271.2.748 [DOI] [PubMed] [Google Scholar]
  • 46.Tsujikawa K, Kawakami N, Uchino Y, Ichijo T, Furukawa T, Saito H, et al. Distinct functions of the two protein tyrosine phosphatase domains of LAR (leukocyte common antigen-related) on tyrosine dephosphorylation of insulin receptor. Mol Endocrinol. 2001;15(2):271–80. doi: 10.1210/mend.15.2.0592 [DOI] [PubMed] [Google Scholar]
  • 47.Benmimoun B, Polesello C, Waltzer L, Haenlin M. Dual role for Insulin/TOR signaling in the control of hematopoietic progenitor maintenance in Drosophila. Development. 2012;139(10):1713–7. doi: 10.1242/dev.080259 [DOI] [PubMed] [Google Scholar]
  • 48.Kaur H, Sharma SK, Mandal S, Mandal L. Lar maintains the homeostasis of the hematopoietic organ in Drosophila by regulating insulin signaling in the niche. Development. 2019;146(24):dev178202. doi: 10.1242/dev.178202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Handke B, Poernbacher I, Goetze S, Ahrens CH, Omasits U, Marty F, et al. The hemolymph proteome of fed and starved Drosophila larvae. PLoS One. 2013;8(6):e67208. doi: 10.1371/journal.pone.0067208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Shim J, Mukherjee T, Banerjee U. Direct sensing of systemic and nutritional signals by haematopoietic progenitors in Drosophila. Nat Cell Biol. 2012;14(4):394–400. doi: 10.1038/ncb2453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Cho B, Spratford CM, Yoon S, Cha N, Banerjee U, Shim J. Systemic control of immune cell development by integrated carbon dioxide and hypoxia chemosensation in Drosophila. Nat Commun. 2018;9(1):2679. doi: 10.1038/s41467-018-04990-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Oyallon J, Vanzo N, Krzemień J, Morin-Poulard I, Vincent A, Crozatier M. Two Independent Functions of Collier/Early B Cell Factor in the Control of Drosophila Blood Cell Homeostasis. PLoS One. 2016;11(2):e0148978. doi: 10.1371/journal.pone.0148978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ferveur JF, Störtkuhl KF, Stocker RF, Greenspan RJ. Genetic feminization of brain structures and changed sexual orientation in male Drosophila. Science. 1995;267(5199):902–5. doi: 10.1126/science.7846534 [DOI] [PubMed] [Google Scholar]
  • 54.Argue KJ, Neckameyer WS. Altering the sex determination pathway in Drosophila fat body modifies sex-specific stress responses. Am J Physiol Regul Integr Comp Physiol. 2014;307(1):R82-92. doi: 10.1152/ajpregu.00003.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Sethi S, Lin H-H, Shepherd AK, Volkan PC, Su C-Y, Wang JW. Social Context Enhances Hormonal Modulation of Pheromone Detection in Drosophila. Curr Biol. 2019;29(22):3887-3898.e4. doi: 10.1016/j.cub.2019.09.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hoxha V, Lama C, Chang PL, Saurabh S, Patel N, Olate N, et al. Sex-specific signaling in the blood-brain barrier is required for male courtship in Drosophila. PLoS Genet. 2013;9(1):e1003217. doi: 10.1371/journal.pgen.1003217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Rubinstein CD, Rivlin PK, Hoy RR. Genetic feminization of the thoracic nervous system disrupts courtship song in male Drosophila melanogaster. J Neurogenet. 2010;24(4):234–45. doi: 10.3109/01677063.2010.519805 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Houot B, Gigot V, Robichon A, Ferveur J-F. Free flight odor tracking in Drosophila: Effect of wing chemosensors, sex and pheromonal gene regulation. Sci Rep. 2017;7:40221. doi: 10.1038/srep40221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lu B, Zelle KM, Seltzer R, Hefetz A, Ben-Shahar Y. Feminization of pheromone-sensing neurons affects mating decisions in Drosophila males. Biol Open. 2014;3(2):152–60. doi: 10.1242/bio.20147369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Baker KD, Thummel CS. Diabetic larvae and obese flies-emerging studies of metabolism in Drosophila. Cell Metab. 2007;6(4):257–66. doi: 10.1016/j.cmet.2007.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Bull JJ. Sex determining mechanisms: an evolutionary perspective. Experientia. 1985;41(10):1285–96. doi: 10.1007/BF01952071 [DOI] [PubMed] [Google Scholar]
  • 62.Belote JM, McKeown M, Boggs RT, Ohkawa R, Sosnowski BA. Molecular genetics of transformer, a genetic switch controlling sexual differentiation in Drosophila. Dev Genet. 1989;10(3):143–54. doi: 10.1002/dvg.1020100304 [DOI] [PubMed] [Google Scholar]
  • 63.Boggs RT, Gregor P, Idriss S, Belote JM, McKeown M. Regulation of sexual differentiation in D. melanogaster via alternative splicing of RNA from the transformer gene. Cell. 1987;50(5):739–47. doi: 10.1016/0092-8674(87)90332-1 [DOI] [PubMed] [Google Scholar]
  • 64.Ryner LC, Goodwin SF, Castrillon DH, Anand A, Villella A, Baker BS, et al. Control of male sexual behavior and sexual orientation in Drosophila by the fruitless gene. Cell. 1996;87(6):1079–89. doi: 10.1016/s0092-8674(00)81802-4 [DOI] [PubMed] [Google Scholar]
  • 65.Rideout EJ, Narsaiya MS, Grewal SS. The Sex Determination Gene transformer Regulates Male-Female Differences in Drosophila Body Size. PLoS Genet. 2015;11(12):e1005683. doi: 10.1371/journal.pgen.1005683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.DeFalco T, Camara N, Le Bras S, Van Doren M. Nonautonomous sex determination controls sexually dimorphic development of the Drosophila gonad. Dev Cell. 2008;14(2):275–86. doi: 10.1016/j.devcel.2007.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Argue KJ, Neckameyer WS. Altering the sex determination pathway in Drosophila fat body modifies sex-specific stress responses. Am J Physiol Regul Integr Comp Physiol. 2014;307(1):R82-92. doi: 10.1152/ajpregu.00003.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Hong S-T, Bang S, Paik D, Kang J, Hwang S, Jeon K, et al. Histamine and its receptors modulate temperature-preference behaviors in Drosophila. J Neurosci. 2006;26(27):7245–56. doi: 10.1523/JNEUROSCI.5426-05.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Padmanabha D, Baker KD. Drosophila gains traction as a repurposed tool to investigate metabolism. Trends Endocrinol Metab. 2014;25(10):518–27. doi: 10.1016/j.tem.2014.03.011 [DOI] [PubMed] [Google Scholar]
  • 70.Hao Y, Jin LH. Dual role for Jumu in the control of hematopoietic progenitors in the Drosophila lymph gland. Elife. 2017;6:e25094. doi: 10.7554/eLife.25094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Testa ND, Ghosh SM, Shingleton AW. Sex-specific weight loss mediates sexual size dimorphism in Drosophila melanogaster. PLoS One. 2013;8(3):e58936. doi: 10.1371/journal.pone.0058936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.De Groef S, Ribeiro Lopes M, Winant M, Rosschaert E, Wilms T, Bolckmans L, et al. Reference genes to study the sex-biased expression of genes regulating Drosophila metabolism. Sci Rep. 2024;14(1):9518. doi: 10.1038/s41598-024-58863-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Millington JW, Brownrigg GP, Chao C, Sun Z, Basner-Collins PJ, Wat LW, et al. Female-biased upregulation of insulin pathway activity mediates the sex difference in Drosophila body size plasticity. Elife. 2021;10:e58341. doi: 10.7554/eLife.58341 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kurz CL, Charroux B, Chaduli D, Viallat-Lieutaud A, Royet J. Peptidoglycan sensing by octopaminergic neurons modulates Drosophila oviposition. eLife. 2017;6:e21937. doi: 10.7554/eLife.21937 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Urwyler O, Izadifar A, Vandenbogaerde S, Sachse S, Misbaer A, Schmucker D. Branch-restricted localization of phosphatase Prl-1 specifies axonal synaptogenesis domains. Science. 2019;364(6439):eaau9952. doi: 10.1126/science.aau9952 [DOI] [PubMed] [Google Scholar]
  • 76.Masuzzo A, Manière G, Viallat-Lieutaud A, Avazeri É, Zugasti O, Grosjean Y, et al. Peptidoglycan-dependent NF-κB activation in a small subset of brain octopaminergic neurons controls female oviposition. Elife. 2019;8:e50559. doi: 10.7554/eLife.50559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Taylor K, Kimbrell DA. Host immune response and differential survival of the sexes in Drosophila. Fly (Austin). 2007;1(4):197–204. doi: 10.4161/fly.5082 [DOI] [PubMed] [Google Scholar]
  • 78.Shahrestani P, Chambers M, Vandenberg J, Garcia K, Malaret G, Chowdhury P, et al. Sexual dimorphism in Drosophila melanogaster survival of Beauveria bassiana infection depends on core immune signaling. Sci Rep. 2018;8(1):12501. doi: 10.1038/s41598-018-30527-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Sawala A, Gould AP. The sex of specific neurons controls female body growth in Drosophila. PLoS Biol. 2017;15(10):e2002252. doi: 10.1371/journal.pbio.2002252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Millington JW, Rideout EJ. Sex differences in drosophila development and physiology. Curr Opin Physiol. 2018;6:46–56. doi: 10.1016/j.cophys.2018.04.002 [DOI] [Google Scholar]
  • 81.Ramond E, Meister M, Lemaitre B. From Embryo to Adult: Hematopoiesis along the Drosophila Life Cycle. Dev Cell. 2015;33(4):367–8. doi: 10.1016/j.devcel.2015.05.002 [DOI] [PubMed] [Google Scholar]
  • 82.Girard JR, Goins LM, Vuu DM, Sharpley MS, Spratford CM, Mantri SR, et al. Paths and pathways that generate cell-type heterogeneity and developmental progression in hematopoiesis. Elife. 2021;10:e67516. doi: 10.7554/eLife.67516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Krzemien J, Oyallon J, Crozatier M, Vincent A. Hematopoietic progenitors and hemocyte lineages in the Drosophila lymph gland. Dev Biol. 2010;346(2):310–9. doi: 10.1016/j.ydbio.2010.08.003 [DOI] [PubMed] [Google Scholar]
  • 84.Spratford CM, Goins LM, Chi F, Girard JR, Macias SN, Ho VW, et al. Intermediate progenitor cells provide a transition between hematopoietic progenitors and their differentiated descendants. Development. 2021;148(24):dev200216. doi: 10.1242/dev.200216 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Goins LM, Girard JR, Mondal BC, Buran S, Su CC, Tang R, et al. Wnt signaling couples G2 phase control with differentiation during hematopoiesis in Drosophila. Dev Cell. 2024;59(18):2477-2496.e5. doi: 10.1016/j.devcel.2024.05.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Marcetteau J, Duarte P, Leitão AB, Sucena É. Transdifferentiation of plasmatocytes to crystal cells in the lymph gland of Drosophila melanogaster. EMBO Rep. 2025;26(8):2077–97. doi: 10.1038/s44319-025-00366-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Benmimoun B, Polesello C, Haenlin M, Waltzer L. The EBF transcription factor Collier directly promotes Drosophila blood cell progenitor maintenance independently of the niche. Proc Natl Acad Sci U S A. 2015;112(29):9052–7. doi: 10.1073/pnas.1423967112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Brandt SM, Schneider DS. Bacterial infection of fly ovaries reduces egg production and induces local hemocyte activation. Dev Comp Immunol. 2007;31(11):1121–30. doi: 10.1016/j.dci.2007.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Abrams J. Faculty opinions recommendation of aging of the innate immune response in drosophila melanogaster. Faculty Opinions. 2005. doi: 10.3410/f.1024826.292872 [DOI] [Google Scholar]
  • 90.Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118(2):401–15. doi: 10.1242/dev.118.2.401 [DOI] [PubMed] [Google Scholar]
  • 91.Lee G, Park JH. Hemolymph sugar homeostasis and starvation-induced hyperactivity affected by genetic manipulations of the adipokinetic hormone-encoding gene in Drosophila melanogaster. Genetics. 2004;167(1):311–23. doi: 10.1534/genetics.167.1.311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Avet-Rochex A, Boyer K, Polesello C, Gobert V, Osman D, Roch F, et al. An in vivo RNA interference screen identifies gene networks controlling Drosophila melanogaster blood cell homeostasis. BMC Dev Biol. 2010;10:65. doi: 10.1186/1471-213X-10-65 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Khadilkar RJ, Vogl W, Goodwin K, Tanentzapf G. Modulation of occluding junctions alters the hematopoietic niche to trigger immune activation. Elife. 2017;6:e28081. doi: 10.7554/eLife.28081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Ho KYL, Carr RL, Dvoskin AD, Tanentzapf G. Kinetics of blood cell differentiation during hematopoiesis revealed by quantitative long-term live imaging. Elife. 2023;12:e84085. doi: 10.7554/eLife.84085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Meller VH, Wu KH, Roman G, Kuroda MI, Davis RL. roX1 RNA paints the X chromosome of male Drosophila and is regulated by the dosage compensation system. Cell. 1997;88(4):445–57. doi: 10.1016/s0092-8674(00)81885-1 [DOI] [PubMed] [Google Scholar]
  • 96.Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):W207–12. doi: 10.1093/nar/gkad347 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Pablo Wappner

20 Aug 2025

PGENETICS-D-25-00772

Sex differences in the regulation and function of cellular immunity in Drosophila

PLOS Genetics

Dear Dr. Tanentzapf,

Thank you for submitting your manuscript to PLOS Genetics. After careful consideration, we feel that it has merit but does not fully meet PLOS Genetics's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within 60 days Oct 19 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosgenetics@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgenetics/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Pablo Wappner

Section Editor

PLOS Genetics

Pablo Wappner

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

Journal Requirements:

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Guy Tanentzapf. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosgenetics/s/authorship#loc-author-contributions

2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:

https://journals.plos.org/plosgenetics/s/figures

3) Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well.

State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.".

If you did not receive any funding for this study, please simply state: u201cThe authors received no specific funding for this work.u201d

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The manuscript by Dvoskin et al. provides important and novel insights into how sex differences in immunity are established and how these sex differences influence the size, cellular composition, and bacterial infection response of the Drosophila hematopoietic organ. The manuscript is well written, presents a substantial amount of data (with appropriate sample size and statistical methods), and the findings are thorough and thought-provoking. This is an important piece of work that is appropriate for this journal. However, in my view, additional experiments are needed (or sections need to be rewritten) to support some of the authors’ conclusions fully.

Major comments:

1. The authors report raw PSC numbers that are significantly higher (68±22 for males and 91±24 for females) than those reported by other studies (typically 30-40 cells per lobe). Indeed, in lines 126-127, the authors define the PSC as “a group of a few dozen cells”. Why are their PSC numbers reported throughout the paper significantly higher? If this is simply a difference in analysis methods, this should be noted and explained in the text to give clarity to the reader and so as not to confuse the field.

2. The authors show that crystal cell numbers differ significantly between males and females even after normalizing to body weight. Would normalizing crystal cell numbers to the total lymph gland cell numbers still reveal a difference between sexes? Crystal cell numbers are known to be affected by the lymph gland size, and for this reason, most studies usually report crystal cell percentage rather than raw counts. This analysis could reveal whether the reported correlation between crystal cell number and lymph gland size is similar between the sexes or due to inherent differences in lymph gland size between the sexes.

3. Lines 163-167 say that the authors labeled progenitors with domeMESO GFP, but the figure and figure legend for Figure 1 indicate that the progenitors are labeled by Tep4gal4; UAS-GFP. This should be clarified and corrected in the text and/or figure legends.

4. In fact, throughout the manuscript, the authors use Tep4 and domeMESO drivers interchangeably. However, it is well established that Tep4 is expressed only in core progenitors, whereas domeMESO is expressed in both core and distal progenitors (PMID: 32243888). Several studies (including those from the authors: PMID: 34713801) have shown that genetic manipulations with these drivers can yield different results, especially as these populations are in different stages of the cell cycle and to differentially respond to signaling pathway manipulations (e.g., PMID: 38866012 ; PMID: 39466810). For this reason:

a. For Figure 1, I recommend assessing the number of domeMESO-positive progenitors (as the text mentions) to determine whether they differ significantly between males and females, similar to the analysis for Tep4 progenitors (presumably what was done in Figure 1).

b. The difference between the populations marked by Tep4 and domeMESO should be explained in the text, clearly stating that when using Tep4, these are core progenitors. In contrast, when using domeMESO, the authors can use the term 'progenitors'. And the text describing the results from these figures should be double-checked for accuracy to confirm the correct driver is referenced.

5. For scRNASeq analysis, why weren’t sex differences compared, or results shown for comparisons between proPL, IZ, and PL clusters? The authors noted (lines 200-202) that these clusters were particularly different between sexes in the UMAP, so I am curious why these were not compared. These comparisons should be included for completeness, and if no DEGs were identified, this should be reported by the authors.

a. Interestingly, NimC1 (the antigen for P1 antibody, which the authors use for Plasmatocyte staining and is a marker for PL) was identified as a top overall gene differentially expressed between sexes (in the supplemental table). The authors should consider including it in the bubble plot for Figure 2A.

6. I am not sure I agree with the author’s conclusions about the results from feminizing the progenitors in Figure 5. When comparing males and females in tep4gal4>TraF for nuclei count (Figure 5B), crystal cell count (Figure 5F) and progenitor count (Figure 5J), all of these are no longer significantly different between males and females and thus suggest that feminizing the females and males reverses the sex-bias in these numbers. Furthermore, the interaction constants for nuclei and progenitors are significant in the feminized progenitors experiments. This suggests that indeed some sex differences in the lymph gland are mediated by the progenitors. But I would agree that sex differences in crystal cell number in the lymph gland are not mediated by the Tep4+ progenitors.

a. This data may be difficult to interpret because there are smaller differences between males and females in the tep4-gal4 only controls, but this underscores the need to repeat these experiments with domeMESO-GAL4 to truly conclude that “Sex differences in the lymph gland are not mediated by progenitors” (line 330). Thus, in Figure 5, I suggest using the domeMESO-GAL4 driver to feminize progenitors in addition to Tep4, as this might yield different results

b. Note: the gal4 insertion in Tep4 (from Kyoto DGRC) may disrupt gene function (hence why it cannot go homozygous), and so the smaller differences between males and females in this background may be biologically relevant.

c. Similarly, in Figure 5, I recommend quantifying Tep4-positive core progenitor numbers, as these may show significant differences. Indeed, if that is what was used in Figure 1, there were significant differences in Tep4-positive core progenitors in wildtype and so quantifying those numbers in addition to the domemeso+ progenitors in the feminized backgrounds is essential for making conclusions about the role of progenitors in sex differences.

7. The authors state that “it should become a standard practice to consider sex as a key variable for all phenotypic characterization of the lymph gland.” But the authors also noted that controlling for body weight eliminates most raw count differences for nuclei, PSC, and progenitors (and that there were no differences for plasmatocytes). Most studies do not report raw counts but rather normalized counts to lymph gland size (raw count/total nuclei). Figure 1 should include sex-specific “normalized” values, as this would give important context to interpreting many past experiments.

a. Another important point the authors may want to point out is that earlier work using domeless-GAL4 to drive manipulations in the progenitors (or other GAL4s that are lethal in males) only looked at these manipulations in female animals, as it would be impossible to drive the GAL4 in males as it is lethal. So there could be an important and interesting missing body of data on the impact of some of the same signaling pathways mentioned in the introduction that is yet to be explored (and discrepancies between results from manipulations that use dome-GAL4 and domeMESO-GAL4, which is not lethal in males, could suggest sex-specific effects and would make it that much more essential to take sex into account when analyzing and interpreting results)

Minor Questions:

1. For the insulin pathway experiments, have the authors considered testing additional pathway members, such as expressing a constitutively active form of PI3K or knocking down the kinase Akt?

2. How do PSC feminized males respond to infection with P. carotovorum and E. coli?

Minor Comments:

1. In all figures except for the last two, the labels for nuclei, crystal cells, and progenitors should be in larger, brighter font to improve visibility.

2. In Figure 6, authors should update the labels to match the rest of the figures:

‘Hnt’ to ‘Crystal cells’

‘ToPro’ to Nuclei’

‘domeMESO-GFP’ to ‘Progenitors’

3. Line 138-139 should use the flybase accepted term for dilps (Ilp2 and Ilp6) similar to what is used in Figure 2 or both terms as is used in the discussion (lines 478-480)

4. Typos/misspellings: line 36, 168, 209,

5. Figure call on line 325 may be incorrect

6. Citations are missing after the statement “The PSC has an established role in orchestrating the behaviour of different cell types in the lymph gland” on line 353. These citations are important because the types of differences the PSC has been shown to orchestrate would have an impact on what would be expected from manipulations of sex in the PSC.

7. In line 834, ‘insulin’ should be changed to ‘insulin pathway’, since the experiments involve activating the pathway rather than insulin itself.

8. I appreciated the explanation for why the authors chose the statistical test used in Figure 3 (lines 273-279).

Reviewer #2: In this new manuscript, the authors present a careful and detailed analysis of sex differences in drosophila larval hematopoiesis, in the lymph gland. First they carefully show that overall cellularity and most cell types (but not mature plasmatocytes - Drosophila macrophages) are increased in raw number in females, relative to males. However, when corrected for body weight, only the crystal cell numbers were different between sexes. Reanalyzing previous scRNAseq data (from one of the authors), the team shows clear differences in gene expression across nearly all hematopoietic cell types, via scRNAseq; presumably some of these gene expression changes effect attributes beyond cell number. They then shift to back focusing on the sexual dimporphisms of numbers hemotapoetic cell types, with a carefully controlled analysis of genetically transforming sex, feminizing particular tissue with programmed expression of TraF, a very elegant experimental design made possible with the tools unique to the fly model.

Unfortunately, using these sex transforming tools, the sexually dimorphic gene expression not examined further, which seems like a missed opportunity.

Nonetheless, they do show that sex transformation of the PSC, the developmental/stem cell niche in the lymph gland (but not other cells in the gland nor brain nor fat body) can alter cellularity in otherwise male animals, to mimic the female numbers of total cells and crystal cells, but not others.

Some of this fact of the PSC on cellularity is controlled by Insulin signaling, as shown with PSC-specific Insulin Receptor knockdown or activation, which effects crystal numbers significantly, with a sex:genotype interaction. While the overall cellularity trends in the same direction, the effect is not as robust and lacks a sex:genotype interaction. This finding is reminiscent of the finding in Figure 1, where only the crystal cell numbers were different after correct for body weight. Perhaps the authors should focus on this difference, which seems to represent a true difference in developmental outcomes rather than a difference only in size? At a minimum, some context and connections between this data and earlier data should be included.

In the last section of the manuscript, larvae are feed bacteria, either E. coli or Ecc15. It is not convincing that this E. coli feeding is an "infection", as claimed. The details on the E. coli strain and its virulence are not provided. Ecc15 feeding of larvae is an established infection methodology with clear evidences of both pathology and immune activation. Nonetheless, E. coli feeding show a clear sexually dimorphic effect on crystal cell numbers (these same cells, again!...why always crystal cells? Anything from teh gene expression profile that might inform?),while other cell types maybe change in number, but in a similar pattern in both sexes. Ecc15 feeding showed a similar pattern, with crystal cells significantly increased only in females. The authors make a large, but confusing point, about how this trend did not reach significance in the sex:genotype interaction analysis, but do not provide even a speculation as to why this discrepancy compared to the robust statistical differences for females (***) in the Ecc feed females (only). This particular condition is particular noisy (Figure 10D); perhaps they lack of significance in teh sex:genotype is more of issue with variation rather than a lack of actual interaction? The authors should provide more explanation on this disconnect in their statistical analysis and how it relates (or not) to (potential) real biological outcomes.

Overall, this is a well executed, rigorous study, although much of the data (with the exception of the InR/PSC analysis) is observational, and as the authors write "identifies important areas for future exploration."

Minor comment:

To this reader, the description of how the scRNAseq data was "sexed" seemed a bit off; certainly required careful reading of the Methods. I feel like the analysis was to score cells for the lncRNAs ROX1/2 to define sex, and the rest of the analysis flowed from there. I.e. there is nothing obvious in movie 1, left UMAP to show two groups within each cluster....until you also show the lncRNAs on the same UMAP, middle and right. I suspect this was a eureka moment, when this split was realized (once the sex specific RNAs were re-introduced into the analysis). Nonetheless, please make sure the narrative description of the analysis is complete; to this reader it was a bit confusing in that very first paragraph.

Reviewer #3: Dvoskin et al. investigate the differences in the development of the larval lymph gland between female and male Drosophila. They report that female lymph glands are bigger than male lymph glands, which correlates with the higher body weight of females. The female lymph glands present an excess of crystal cell counts compared to males. They reanalyze lymph gland single-cell RNA sequencing data previously generated by Girard et al. to determine transcriptional differences between males and females for the subgroup of lymph gland hemocytes. Following this, they overexpress traF in neurons, fat body, hemocyte progenitors and posterior signaling center (PSC) to feminize the organs/tissues and determine their roles in the sex biases in lymph gland development. Their findings highlight the PSC, targeted via col-Gal4, and insulin signaling as modulators of lymph gland size (total cell number) and/or crystal cell abundance in males. Finally, they challenge the animals with E. coli and P. carotovorum and show that females respond more strongly to E. coli infection than males.

Overall data and statistics are robust and well-presented. So far, sex differences have not been taken systematically into account while it has become clear that they are important parameters to document and consider in most studies. Thus, the discoveries presented in the manuscript are novel and will be relevant for a broad audience.

Major comments:

1. Data on the specificity of the drivers used in this study are essential, as expression in other tissues has been previously reported (DOI: 10.1002/dvg.23600, https://doi.org/10.7554/eLife.61409 as an example). This is particularly relevant for Col-Gal4 which is expressed, as tep4-Gal4, in other tissues/cells including the posterior lobes of the lymph gland (https://doi.org/10.7554/eLife.61409), thus impacting the interpretation of the lymph gland PSC as a mediator of sex specificity in the lymph gland.

2. The authors do not document the efficiency of the genetic tools used in the experiments. The manuscript's main message is that females and males are not equivalent. Yet the authors do not show that the drivers used in their gain-of-function experiments are expressed at similar levels in both sexes and thus cannot exclude that the phenotypes may be at least in part due to different induction levels of UAS transgenes.

3. The authors use RNAi to knock down InR in the lymph gland. A single RNAi construct is used and no validation of the efficiency of the construct is presented.

4. Given that two thirds of the adult hemocytes originate from the embryo rather than from the lymph gland, and that those hemocytes can provide systemic signals, could the authors check whether the embryonically derived hemocytes also show sexual dimorphism? If so, the authors should evoke/discuss the possibility that those cells may also affect the lymph gland sex specific phenotypes and account for different effects in the adult as well.

5. The manuscript describes differential expression of sex-determination genes following segregation of male and female lymph gland cells (lines 227–230). However, despite strong enrichment of lncRNA:roX1 and lncRNA:roX2, expression of msl-2 is low and restricted to a small fraction of male cells, while Sxl and tra show only marginal sex-based differences. Providing absolute expression levels of these genes, to be compared with other clusters’ genes/markers, would help interpretation. Also, tra and sxl are expressed in both sexes, then differentially spliced in females and males. Were the female specific isoforms taken into account in their analysis?

Furthermore, the sex-biased expression of TkR99D, rdgA, Ilp6, and MCTS1 in the PSC raises interesting questions. Do these genes have known roles in crystal cell biology? Are their expression levels affected in col>traF or col>InR RNAi contexts?

6. Fig 3 panels E and F show that crystal cells show no sex difference in the driver control. Given this data, it is hard to conclude that neuronal derived feminizing signals do not act on the lymph gland. Perhaps using a different neuronal driver will help circumventing this issue and eliminating confounding results.

7. The authors utilize the overexpression of the traF gene in CNS, fat body, lymph gland progenitors and PSC to “feminize” these tissues. To support this strategy, authors may want to elaborate on the cellular/molecular impact of traF overexpression on these tissues. For instance, are there differences in size? Do they show altered expression of sex-related or sex-specific genes?

8. Along this line, since male PSC driven feminization via traF overexpression leads to a crystal cell number phenotype similar to that obtained upon inactivation of the Insulin Receptor (InR) in males, could the authors assess the levels of InR expression in the traF overexpressing male PSC? This will corroborate the statement made at line 414: ‘the insulin pathway in the PSC mediates sex differences in crystal cell number’ an in the discussion at line 456.

9. While the increase in crystal cell number upon col>traF or col>InR RNAi is clear, this is unlikely to explain the observed increase in total nuclei in the primary lobe. Given that the number of dome+ progenitors remain unchanged, investigating the impact on other hemocyte subtypes (e.g., differentiated plasmatocytes) would help explaining how modulating sex-determination impact the lymph gland.

10. How do the authors account for effects coming from different genetic backgrounds, which may confound the interpretation of some data? For example, Fig 3 panels A and B show differences in the nuclear count between control females and males. In other controls, there is no such difference, see Fig 5 panels A,B (driver control).

11. The authors state (lines 269-271) that to control for differences in the genetic backgrounds, they use two controls (driver alone, UAS transgene alone in heterozygous conditions). Yet, they introduce differences in the genetic background with domeMesoGFP. The Gal4 controls are obtained by crossing Gal4 lines with domeMesoGFP (final genotype Gal4/+; domeMesoGFP/+) and the UAS control by crossing UAS-traF; domeMesoGFP with domeMesoGFP (final genotype UAS-traF/+; domeMesoGFP). Could homozygous domeMesoGFP explain the differences seen in Fig. 3E (males), 3I (females), 4E (males), 4I (females)...? Control by crossing with domeMesoGFP is also used in InR KD/GOF experiments, which produces controls with different genetic backgrounds according to the methods section.

12. The 3D UMAP presented in Movie 1 shows a clear distinction between female and male clusters of hemocytes. The biggest sex-specific distance seems to be observed for the IZ cluster. Why was it disregarded in the analysis?

13. Line 438-439: ‘the magnitude or even the existence of sex-differences in the response to infection may vary depending on the bacterial strain used’. How did the authors control for the absolute and sex specific food intake for the two infection protocols?

14. The observed higher sensitivity of the female lymph gland to E. coli raises the question of whether this contributes to the reported lower survival of adult females upon infection (doi: 10.4161/fly.5082). Is this phenotype dependent on crystal cells, or could other lymph gland-derived or circulating immune cells be involved?

Minor comments:

- Among the identified sex-specific DEGs, authors mention orthologs of human genes involved in blood development and disease. To add weight to this observation, authors may want to provide, if available, additional data on sex-specific expression of the human orthologs and/or gender-bias in disease incidence.

- Line 209: A space is missing.

- Lines 460-461: The authors mention sex differences in the cellular immune response elicited by bacterial infection, referring to the counts of lymph gland hemocytes. In the larva, if the lymph gland is not ruptured, the cellular immune response is provided exclusively by the circulating hemocytes.

- Line 239-241: a molecular validation of some DEG genes would add value to the transcriptomic data (qPCR? In situ hybridization? Immunohistochemistry?)

- The scRNAseq data indicate a significant enrichment of NimC1 in female lymph glands compared to males (Table S1), which does not seem to coincide with the NimC1 labelling and count presented in Figure 1E, E’,J. Can the authors comment on this discrepancy?

- There are mistakes in referring to the supplementary files (line 247-254)

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix. -->-->

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. -->

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Pablo Wappner, Pablo Wappner

23 Feb 2026

PGENETICS-D-25-00772R1

Sex differences in the regulation and function of cellular immunity in Drosophila

PLOS Genetics

Dear Dr. Tanentzapf,

Thank you for submitting your manuscript to PLOS Genetics. After careful consideration, we feel that it has merit but does not fully meet PLOS Genetics's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The revised manuscript was evaluated by two of the three reviewers that analyzed the original version. As you can see below, one of the reviewers was entirely satisfied with the revised manuscript, and recommended acceptance. The other reviewer finds that the manuscript has improved, but still expresses some concerns that need to be attended.

Please submit your revised manuscript by Apr 24 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosgenetics@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgenetics/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Pablo Wappner

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors have thoroughly addressed my major and minor comments, and the revisions have significantly strengthened the manuscript. I appreciate the care taken to clarify the analyses and improve the presentation, and I believe the paper is now much improved. I commend the authors for their thoughtful responses and substantial improvements to the manuscript.

Reviewer #3: The authors have improved the manuscript by adding some experiments and revising the text. With regard to the previously raised points:

Point 1: The authors point to the PSC as a mediator of sex specificity in the lymph gland, making it essential to address concerns regarding the specificity of the drivers used, particularly col-Gal4, which is expressed not only in the primary lobe’s PSC but also in other lymph gland lobes at late larval stage. To address this, the authors assessed colocalization between col-Gal4 and Antp in the primary lobe. However, this does not resolve the issue of potential unspecific effects. While we acknowledge the challenge of specific tools and appreciate the expanded discussion, the authors could for instance compare col expression across different sites to better estimate the possible contribution of these tissues. Earlier developmental stages may be also examined, when expression from posterior lobes should have less pronounced impact.

Point 3: To address the lack of validation for the experiments performed using a sole RNAi line targeting InR, the authors cite two studies in which this RNAi line was used. However, none of these studies directly test the ability of such RNAi to decrease InR expression and only in Urwyler et al alternative strategies were used to confirm the results obtained with this RNAi line. Authors may want to cite this work only to sustain the claim that “their effectiveness at modifying InR activity is well established [80-81].”

Points 6 and 7: The authors aim to test whether sex-specific traits in the lymph gland are controlled by CNS sex by feminizing the CNS through TraF overexpression using the elav-Gal4 driver. To support their approach, they now cite studies reporting TraF-induced feminization, yet none use elav-Gal4, leaving unresolved whether this approach is sufficient to induce CNS feminization and calling for experimental validations. Feminization of cells expressing the elav driver should be validated by qPCR assays on known sex specific genes. Could the authors clarify what they mean by “we failed to set this experiment in context” or provide more fitting reference, if available?

Moreover, the elav-Gal4 driver show genetic background issues, as control males do not display significantly reduced CC and progenitor numbers in the lymph gland. Although one alternative driver was tested, additional drivers for elav or other pan-neuronal markers could have been explored. In this context, the data mentioned in the rebuttal letter using the alternative C2-Gal4 driver should have been shown and a reference for that driver as well.

The title of the paragraph ‘We find no evidence that Sex differences in the lymph gland are mediated by the CNS’ does not fit with the statement “we were unable to find conclusive evidence in data and subsequent statistical analysis for the interpretation that sex differences in the lymph gland were mediated by the CNS” (lines 315–317). Either the limitations of their approach are more clearly explicated to place the conclusion in a more rigorous context or the data should be removed.

Point 8: As the authors could not assess InR expression levels upon TraF overexpression in the PSC (using approaches that they do not specify in their response), it would be appropriate to explicitly acknowledge the possibility that pathways other than InR may contribute to sex differences in crystal cell number. Moreover, a comparison of the fold-change in crystal cell numbers upon TraF overexpression versus InR knockdown in the PSC could already provide a base for some speculations on this matter.

Point 11: Authors may wish to comment on how the DEGs and pathways identified in their RNA-seq analysis—now expanded to additional lymph gland clusters—relate to the differential responses of male and female lymph gland populations to bacterial infection or the insulin pathway.

I am not sure the authors address Point 9 (see our revision in 2025): While the increase in crystal cell number upon col>traF or col>InR RNAi is clear, this is unlikely to explain the observed increase in total nuclei in the primary lobe. Given that the number of dome+ progenitors remains unchanged, investigating the impact on other hemocyte subtypes (e.g., differentiated plasmatocytes) would help explaining how modulating sex-determination impact the lymph gland.

Minor points

- Line 590: “we” to be removed.

- It is unclear why data on collier-Gal4 are mentioned in line 179.

- Line 255: Figure 1B should be Figure 2B.

- Figure 9L’: plasmatocyte is misspelled

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics  data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: None

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

Figure resubmission:

While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.

-->

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript. -->

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 2

Pablo Wappner, Pablo Wappner, Pablo Wappner

28 Apr 2026

Dear Dr Tanentzapf,

We are pleased to inform you that your manuscript entitled "Sex differences in the regulation and function of cellular immunity in Drosophila" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Pablo Wappner

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

BlueSky: @plos.bsky.social

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly:

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-25-00772R2

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Pablo Wappner, Pablo Wappner, Pablo Wappner

PGENETICS-D-25-00772R2

Sex differences in the regulation and function of cellular immunity in Drosophila

Dear Dr Tanentzapf,

We are pleased to inform you that your manuscript entitled "Sex differences in the regulation and function of cellular immunity in Drosophila " has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Sharmila Kamatchi

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Movie. Three dimensional UMAP visualization of single-cell sequencing data showing cells from three biological replicate samples (21,157 total cells), each containing a mixed population of lymph gland primary lobes from 5 male and 6 female larvae.

    Graph based clusters defining lymph gland cell types (left panel) and expression of the male-specific genes lncRNA:roX1 (middle panel) and lncRNA:roX2 (right panel) visualized on the UMAP. PSC, posterior signaling center; MZ, medullary zone; IZ, intermediate progenitor; proPL, proplasmatocyte; PL, plasmatocyte; CC, crystal cell; X, mitotic cluster.

    (MOV)

    Download video file (7MB, mov)
    S1 File. Anova analysis was used to determine fold change in the number of reads for each gene, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

    We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

    (PDF)

    pgen.1012151.s002.pdf (223.2KB, pdf)
    S2 File. Anova analysis was used to determine fold change in the number of reads for each gene in the MZ, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

    We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

    (PDF)

    pgen.1012151.s003.pdf (224.9KB, pdf)
    S3 File. Anova analysis was used to determine fold change in the number of reads for each gene in the crystal cells, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

    We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

    (PDF)

    pgen.1012151.s004.pdf (200.3KB, pdf)
    S4 File. Anova analysis was used to determine fold change in the number of reads for each gene in the PSC, comparing female cells to male cells, as distinguished by expression of roX1 and rox2.

    We set a threshold of 1.5 fold change, and <=0.0001 for the FDR step-up, discarding any genes which did not meet both thresholds.

    (PDF)

    pgen.1012151.s005.pdf (308.4KB, pdf)
    S5 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster overall.

    (PDF)

    pgen.1012151.s006.pdf (167.8KB, pdf)
    S6 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the MZ.

    (PDF)

    pgen.1012151.s007.pdf (157.9KB, pdf)
    S7 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the crystal cells.

    (PDF)

    pgen.1012151.s008.pdf (152.6KB, pdf)
    S8 File. Using g:Profilers’s g:GOSt tool for gene-set enrichment analysis we analyzed lists of unique DEGs from S4 File (see highlighted columns) to find gene ontology terms, pathways, and transcription factor targets that are enriched in each sex and cluster in the PSC.

    (PDF)

    pgen.1012151.s009.pdf (158.2KB, pdf)
    S9 File. A selection of interesting sex-specific DEGs for further study.

    These genes were selected for being enriched in one cell type, being broadly conserved across species (including in humans in most cases), and having some connection to blood cell development or disease, or immune cell phenotypes. References are included for each gene detailing the known roles of these genes or their mammalian orthologs in blood cell development, disease, or phenotypes.

    (PDF)

    pgen.1012151.s010.pdf (83.8KB, pdf)
    S10 File. We used the multiple list comparator from molbiotools to compare DEG lists from Table 1 and determine which genes were uniquely overexpressed in each cluster.

    We ran this analysis both with and without the ‘overall’ category, which refers to the comparison of total male and female lymph gland cells.

    (PDF)

    pgen.1012151.s011.pdf (292.4KB, pdf)
    S1 Table. Total counts for sex determination genes.

    Total number of sex determination genes separated by males and females, as well as total counts per cell.

    (PDF)

    pgen.1012151.s012.pdf (22.3KB, pdf)
    S1 Fig. Differences between collier+ and Antp+ cell counts.

    Total cell count for both collier+ PSC cells (expressing GFP through collier-gal4) as well as Antp+ cells (stained with Antp antibody) in males and females. A significant difference was found in females between the two cell types (p = 0.0029). A significant difference was found in males between the two cell types (p = 0.0003).

    (TIF)

    pgen.1012151.s013.tif (70.5KB, tif)
    S2 Fig. Mean Intensity of colliergal4 and tep4gal4 Mean intensity of both collier+ and tep4+ cells measured for both males and females using ImageJ.

    (TIF)

    pgen.1012151.s014.tif (66.8KB, tif)
    S3 Fig. Raw cell counts from main text Fig 1H-1L corrected by dividing each female data point by average total lymph gland nuclei count (main text Fig 1G) and dividing each male data point by average phenotype weight (main text Fig 1G).

    (A) Corrected number of PSC cells (Antp+) (female n = 64, male n = 59, p = 0.7819). (B) Corrected number of core progenitors (tep4+) (female n = 64, male n = 59, p = 0.9705). (C) Corrected number of crystal cells (Hnt+) (female n = 25, male n = 19, p = 0.0056). (D) Corrected number of plasmatocytes (P1+) (female n = 30, male n = 22, p = 0.4531). (E) Corrected number total progenitors (domeMESO+) (female = 24, male = 26, p = 0.6048). **** indicates P < 0.0001, *** indicates P < 0.001, ** indicates P < 0.01, * indicates P < 0.05, ns (non-significant) indicates P > 0.05. Error bars are 95% CI.

    (TIF)

    pgen.1012151.s015.tif (94.9KB, tif)
    S4 Fig. Crystal cell counts corrected for body and lymph gland size.

    (A) Raw cell counts for crystal cells in w1118 x tep4GFP male and female larvae show a significant difference (p < 0.0001). (B) Total cell counts for crystal cells in w1118 x tep4GFP male and female larvae, corrected for body size, show a significant difference (p = 0.0056). (C)Total cell counts for crystal cells in w1118 x tep4GFP male and female larvae, corrected for total lymph gland size (total nuclei count for each lobe corresponding to crystal cell number data point), show a significant difference (p = 0.0011).

    (TIF)

    pgen.1012151.s016.tif (95.4KB, tif)
    S5 Fig. Feminization with c2-gal4 (A-B) Raw cell counts for total number of nuclei, stained with ToPro.

    Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 female control (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control females (n = 27), c2-Gal4 control males (n = 21),c2-Gal4 feminized males (n = 16), UAS TraF control males (n = 21). The genotype:sex interaction constant was not significant (p = 0.4208). (C-D) Raw cell counts for total number of crystal cells, stained with Hnt. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 control (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control (n = 18), c2-Gal4 control males (n = 21), c2-Gal4 feminized males (n = 16), UAS TraF control males (n = 24). The genotype:sex interaction constant was not significant (p = 0.7396). (E-F) Raw cell counts for total number of progenitors, expressing GFP in domeMESO+ cells. Quantification using a two-way ANOVA, post-hoc Tukey’s test, for: c2-Gal4 control females (n = 22), c2-Gal4 feminized females (n = 23), UAS TraF control females(n = 27), c2-Gal4 control males (n = 21), c2-Gal4 feminized males (n = 16), UAS TraF control males(n = 21). The genotype:sex interaction constant was not significant (p = 0.0590).

    (TIF)

    pgen.1012151.s017.tif (315.1KB, tif)
    S6 Fig. domeMESO gal4 based feminization of progenitors.

    A) Raw cell counts for total number of nuclei. A 2 way ANOVA, Tukey’s test showed: no significance between domeMESO gal4 control females and domeMESOgal4 feminized females (p = 0.7209), a significant difference between UAS TraF control females and domeMESOgal4 feminized females (p = 0.0005), no significance between domeMESO control males and domeMESO feminized males (p = 0.9949), and no significance between UAS TraF control males and domeMESO feminized males (p = 0.2093). The genotype:sex interaction constant was not significant (p = 0.1876). (B) Raw cell counts for total number of nuclei comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.4752), no significant difference between domeMESO gal4 feminized females and males (p = 0.1425), and a significant difference between UAS TraF control females and males (p < 0.0001). (C) Raw cell counts for total number of crystal cells. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and domeMESO gal4 feminized females (p = 0.2599),no significant difference between UAS TraF control females and domeMESO gal4 feminized females(p > 0.9999), no significant difference between domeMESO gal4 control males and domeMESO gal4 feminized males (p = 0.2422), and no significant difference between UAS TraF control males and domeMESO gal4 feminized males (p = 0.9452). The genotype:sex interaction constant was not significant (p = 0.7756). (D) Raw cell counts for total number of crystal cells comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.1782), no significant difference between domeMESO gal4 feminized females and males (p = 0.3322), and a significant difference between UAS TraF control females and males (p = 0.0032). (E) Raw cell counts for total number of domeMESO+ progenitors. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and domeMESO gal4 feminized females (p > 0.9999), a significant difference between UAS TraF control females and domeMESO gal4 feminized females (p < 0.0001), no significant difference between domeMESO gal4 control males and domeMESO gal4 feminized males (p = 0.9393), and a significant difference between UAS TraF control males and domeMESO gal4 feminized males (p = 0.0001). The genotype:sex interaction constant was significant (p = 0.0252). (F) Raw cell counts for total number of domeMESO+ progenitors comparing females and males of each group. A 2 way ANOVA, Tukey’s test showed: no significant difference between domeMESO gal4 control females and males (p = 0.5104), no significant difference between domeMESO gal4 feminized females and males(p = 0.1194), and a significant difference between UAS TraF control females and males (p < 0.0001).

    (TIF)

    pgen.1012151.s018.tif (315.1KB, tif)
    S7 Fig. Heterozygous/Homozygous domeMESOGFP.

    Heterozygous cross of UAS TraF; + x domeMESOGFP and homozygous cross of UAS TraF;domeMESOGFP x domeMESOGFP, separated by sex. (A) Raw total nuclei count of heterozygous females(n = 17) and homozygous females(n = 16) are shown to have no significant difference (p = 0.2208). (B) Raw total nuclei count of heterozygous males(n = 21) and homozygous males (n = 16) are shown to have no significant difference (p = 0.2259). (C) Significant difference between heterozygous females and males (p = 0.0007), and significant difference between homozygous females and males (p = 0.0067). (D) Raw crystal cell count of heterozygous females (n = 17) and homozygous females (n = 16) are shown to have no significant difference (p = 0.3339). (E) Raw crystal cell count of heterozygous males (n = 21) and homozygous males (n = 16) are shown to have no significant difference (p = 0.6017). (F) Significant difference between heterozygous females and males (p = 0.0463), and significant difference between homozygous females and males (p < 0.0001). (G) Raw domeMESO+ progenitor count of heterozygous females (n = 17) and homozygous females (n = 16) are shown to have no significant difference (p = 0.7122). (H) Raw domeMESO+ progenitor count of heterozygous males (n = 19) and homozygous males (n = 16) are shown to have no significant difference (p = 0.9136). (I) Significant difference between heterozygous females and males (p = 0.0022), and significant difference between homozygous females and males (p = 0.0025).

    (PDF)

    pgen.1012151.s019.pdf (541.2KB, pdf)
    S1 Data. All raw and corrected cell counts for male and female w1118 x tep4 GFP wildtype flies.

    (PDF)

    pgen.1012151.s020.pdf (79.9KB, pdf)
    S2 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 3 (CNS feminization), including both UAS and gal4 controls, and feminized experimental group.

    (PDF)

    pgen.1012151.s021.pdf (55.3KB, pdf)
    S3 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 4 (fat body feminization), including both UAS and gal4 controls, and feminized experimental group.

    (PDF)

    pgen.1012151.s022.pdf (59.6KB, pdf)
    S4 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 5 (domeMESO+ progenitor feminization), including both UAS and gal4 controls, and feminized experimental group.

    (PDF)

    pgen.1012151.s023.pdf (57.9KB, pdf)
    S5 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 6 (PSC feminization), including both UAS and gal4 controls, and feminized experimental group.

    (PDF)

    pgen.1012151.s024.pdf (58KB, pdf)
    S6 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 7 (insulin receptor knockdown in the PSC), including both UAS and gal4 controls, and experimental group.

    (PDF)

    pgen.1012151.s025.pdf (60KB, pdf)
    S7 Data. All raw cell counts for total nuclei, crystal cells, and domeMESO+ progenitors for Fig 8 (constitutively active insulin receptor in the PSC), including both UAS and gal4 controls, and experimental group.

    (PDF)

    pgen.1012151.s026.pdf (59.6KB, pdf)
    S8 Data. All raw cell counts for total nuclei, crystal cells, domeMESO+ progenitors, and plasmatocytes for Fig 9, including both control and infected males and females with E.coli.

    (PDF)

    pgen.1012151.s027.pdf (55.7KB, pdf)
    S9 Data. All raw cell counts for total nuclei, crystal cells, domeMESO+ progenitors, and plasmatocytes for Fig 10, including both control and infected males and females with P.carotovorum.

    (PDF)

    pgen.1012151.s028.pdf (55.4KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pgen.1012151.s030.docx (5.7MB, docx)
    Attachment

    Submitted filename: Response to Reviewers2.docx

    pgen.1012151.s031.docx (463.1KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS Genetics are provided here courtesy of PLOS

    RESOURCES